KASPP (LRRK2) gene, its production and use for the detection and treatment of neurodegenerative disorders

ABSTRACT

The present invention refers to a newly discovered gene named KASPP for Kinase Associated with Parkinsonism with Pleiomorphic Pathology or alternatively named LRRK2 for Leucine-Rich Repeat Kinase 2, its production, biochemical characterization and use for the detection and treatment of neurodegenerative disorders, such as Parkinson disease (PD) including, without limitation, sporadic PD, Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), and other synucleinopathies and/or tauopathy as well as several polymorphisms and mutations in the KASPP/LRRK2 gene segregated with PD.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No.11/665,875, filed Apr. 19, 2007, which is the U.S. National Stage ofInternational Application No. PCT/EP2005/010428, filed Sep. 27, 2005,which claims benefit of U.S. Provisional Patent Application Nos.60/620,893, filed Oct. 21, 2004, and 60/621,169, filed Oct. 22, 2004,each of which is hereby incorporated by reference.

STATEMENT AS TO FEDERALLY FUNDED RESEARCH

This invention was made with government support under NS040256 awardedby National Institute of Neurological Disorders and Stroke. Thegovernment has certain rights in the invention.

The present invention refers to a newly discovered gene named KASPP forKinase Associated with Parkinsonism with Pleiomorphic Pathology oralternatively named LRRK2 for Leucine-Rich Repeat Kinase 2, itsproduction, biochemical characterization and use for the detection andtreatment of neurodegenerative disorders, such as Parkinson disease (PD)including, without limitation, sporadic PD, Alzheimer disease (AD),amyotrophic lateral sclerosis (ALS), and other synucleinopathies and/ortauopathy as well as several polymorphisms and mutations in theKASPP/LRRK2 gene segregated with PD.

Parkinson's disease (PD) is the second most neurodegenerative disorderaffecting 1-2% of the population aged 65 and older characterized by aprogressive loss of dopaminergic neurons of the substantia nigra,associated with the formation of fibrillar aggregates composed ofα-synuclein and other proteins (Lewy bodies and Lewy neurites). In mostcases, PD occurs as a sporadic disease of unknown etiology, but in rareinstances, point mutations or multiplications of the α-synuclein genecan cause autosomal-dominant parkinsonism which resembles the sporadicdisease in many aspects. Recessive forms of parkinsonism have beenrecognized, which are caused by mutations in the genes for parkin(Kitada T. et al., Nature, 392, 605-608, 1998), DJ-1 (Bonifati V. etal., Science, 299, 256-259, 2002) and PINK1 (Valente E. M. et al.,Science, 304 (5674), 1158-1160, 2004). Additional loci have been mappedon chromosomes 2p (Gasser T. et al., Nat. Genet., 18, 262-265, 1998),12cen (Funayama M. et al., Ann. Neurol., 51(3), 296-301, 2002), 1q(Hicks A. A. et al., Ann. Neurol., 52(5), 549-555, 2002), and 2q(Pankratz N. et al., Am. J. Hum. Genet., 72(4), 1053-1057, 2003). Inmore than 10% of patients with PD one or more relatives are alsoaffected by this disorder (Elbaz et al., Neurology, 52:1876-82, 1999).However, genetic causes are only very rarely found.

As α-synuclein aggregation is a pathologic feature both in the commonsporadic and a dominantly inherited form of PD, and also in otherneurodegenerative diseases, such as dementia with Lewy bodies (DLB) andmultiple systems atrophy (MSA), those diseases have collectively beencalled “synucleinopathies”. Other forms of parkinsonism are associatedwith the accumulation of filaments composed of the microtubuleassociated protein tau (MAPT). Mutations in this gene explain at least asubgroup of families with frontotemporal dementia with parkinsonism(FTDP-17; Ghetti B. et al., “Frontotemporal dementia and parkinsonismlinked to chromosome 17 associated with tau gene mutations (FTDP-17)”.In: Dickson D. W., “Neurodegeneration: the molecular pathology ofdementia and movement disorders” ISN Neuropath Press, Basal, 86-102,2003), while sporadic cases with tau pathology most commonly present asprogressive supranuclear palsy (PSP) or corticobasal degeneration (CBD).Based on the putative central role of the tau protein in these diseases,they have been called “tauopathies”.

Recently it has been shown that two large families withautosomal-dominant late-onset parkinsonism (families A and D) are linkedto the PARKS-locus on chromosome 12p11.2-q13.1 (OMIM# 607060),originally mapped in a Japanese family by Funayama et al. (Funayama etal., Ann. Neurol., 51(3), 296-301, 2002; Zimprich A. et al., Am. J. Hum.Genet., 74(1), 11-19, 2004).

Now, a haplotype analysis refined the candidate region to a 13 Mbinterval between flanking markers D12S1692 and D12S85. A total of 29genes have been sequenced in that region in two patients from eachfamily (see Table 1).

A whole gene, part of that had previously been deposited underDKFZp434H211 (Accession: XM_(—)058513), has been amplified from humanbrain cDNA using overlapping primers corresponding to publishedsequences of various ESTs and mRNAs. Nevertheless, it became clear fromcross-species sequence alignments that the DKFZp434H211 clone wasincomplete towards the 5′-end.

Surprisingly, several mutations, including missense mutations and asplice site mutation, have been found in newly discovered large genecoding for a multifunctional protein, which is referred to as KinaseASsociated with Parkinsonism with Pleiomorphic Pathology, KASPP. KASPPspans a genomic region of 144 Kb and comprises 51 exons and encodes 2527amino acids (see SEQ ID NOS: 1 and 2 and FIG. 4). The gene can also benamed Leucine-Rich Repeat Kinase 2, LRRK2, because it is the only genein the human genome encoding a kinase containing leucine rich repeatswhich was very surprising. KASPP/LRRK2 is a 285 kD protein.

Therefore, the present invention is directed to an isolated nucleic acidmolecule comprising a polynucleotide sequence selected from:

-   (a) nucleotides 1 to 9104 of SEQ ID NO: 1 or 2;-   (b) nucleotides 1 to 7584 of SEQ ID NO: 1 or 2;-   (c) nucleotides 1 to 7581 of SEQ ID NO: 1 or 2;-   (d) a nucleotide sequence coding for the protein sequence of SEQ ID    NO: 1 or 2 or for the protein sequence of SEQ ID NO: 1 or 2    containing at least one of the mutations depicted in SEQ ID NO: 1 or    2, respectively;-   (e) a nucleotide sequence complementary to either of the nucleotide    sequences in (a), (b), (c) or (d); and/or-   (f) a nucleotide sequence which hybridizes under high stringency    conditions to any of the nucleotide sequences in (a), (b), (c), (d)    or (e).

SEQ ID NO: 2 is particularly preferred because it reflects the aminoacid sequence of human KASPP/LRRK2 and the human nucleotide sequencecoding for the human KASPP/LRRK2.

Examples of polynucleotides selected from paragraph (f), above are thespecific mutations, variants and polymorphisms described herein.

A polymorphism generally is the occurrence of different forms of nucleicacids or proteins in individual organisms or in organisms of the samespecies, independent of sexual variations. According to the presentinvention two different polymorphisms have been found for the humanKASPP/LRRK2. One shows a variation from cytosine to thymidine atposition 635 (c635t) causing a change in the amino acid sequence fromserine to leucine (S212L) (see SEQ ID NOS: 4 and 5). The other shows avariation from thymidine to cytosine at position 7190 causing a changein the amino acid sequence from methionine to threonine (M2397T) (seeSEQ ID NOS: 6 and 7).

Examples of high stringency hybridization conditions can be found e.g.in Ausubel, F. M. et al., Current protocols in Molecular Biology, JohnWily & Sons, Inc., New York, N.Y. (1989). In a particular example, afilter, e.g. a nitrocellulose filter, is incubated overnight at 68° C.with a probe in a hybridization solution e.g. containing 50% formamide,high salt (either 5×SSC [20×: 3M NaCl/0.3M trisodium citrate] or 5×SSPE[20×: 3.6M NaCl/0.2M NaH₂PO₄/0.02M EDTA, pH 7.7]), 5× Denhardt'ssolution, 1% SDS, and 100 μg/ml denatured salmon sperm DNA. This isfollowed by several washes with buffer, e.g. in 0.2×SSC/0.1% SDS at atemperature selected based on the desired stringency and the meltingtemperature (Tm) of the DNA hybrid. For example, 68° C. are appropriatefor high stringency hybridization.

The present invention is also directed to a fragment of the inventivenucleic acid molecule specified above containing at least one of the 51exons and/or coding for at least one of the five domains as specified inFIGS. 4A-4K, FIGS. 5A-5C, and/or FIGS. 11A or 11B of the presentspecification. The boundaries of the exons as specified in FIGS. 4A-4Kare applicable for the nucleotide sequences of SEQ ID NO:1 and SEQ IDNO:2.

In addition, the nucleic acid molecule as specified under (f) above mayconsist of 10 to 50 nucleotides, preferably from 10 to 35 nucleotides,in particular from 20 to 35 nucleotides. Such nucleic acid molecule canbe used as a probe or primer for the detection of the polynucleotide ofthe present invention, in particular for the detection of a mutationthereof as explained in more details below.

Another example of a fragment is a nucleic acid coding for theimmunogenic peptide of SEQ ID NO: 3 and the peptide itself.

Such fragments may be produced synthetically e.g. by nucleic acidsynthesis or by a PCR or TR-PCR reaction.

Therefore, another embodiment of the present invention is directed to anucleic acid molecule containing at least one of the mutations depictedin FIGS. 17A-17K or FIGS. 18A-18K, preferably only one of the mutationsdepicted in FIGS. 17A-17K or FIGS. 18A-18K, e.g., the mutation/s atposition 2378, 2789, 3287, 3342, 3364, 3683, 4321, 5096 and/or 6059. Inaddition, the polymorphisms c635t and t7190c are also a specificembodiment of the present invention.

Surprisingly, is has been discovered that in family A (Y1699C; 5096A>G)and in family D (R1441C; 4321C>T) both mutations segregated with diseasein the families (for pedigree structures see FIG. 1) and were not foundin more than 1000 control individuals, nor in 300 sporadic PD-patients.

In Family A, 16 individuals were typed (8 unaffecteds, 8 affecteds). Allaffecteds were heterozygous for the mutation and all unaffecteds agedover 60 were wild-type. Individuals IV:1 and IV:2 (family A) were notincluded in our initial linkage analysis (Zimprich A. et al., 2004,supra), both individuals have now been genotyped. Recalculation of thetwo-point LOD scores using the mutation as a marker gives maximum LODscores of 3.78 at θ=0.

In Family D, 34 individuals were typed (10 affecteds and 24unaffecteds), all affecteds were heterozygous for the 4321C>T (2.1441C)mutation; out of the 24 clinically unaffected, genotyped individuals,only two were aged over 60 years and were mutation carriers. Theseindividuals are at risk and likely to be presymptomatic given that theaverage age of onset in this family is 65 years according to Wszolek Z.K. et al., Neurology, 62(9), 1619-1622, 2004.

To estimate the prevalence of KASPP/LRRK2-mutations among PD-families,one index patient from 44 additional families with PD, 32 consistentwith autosomal dominant parkinsonism and 12 affected sib-pairs, weresubsequently sequenced.

Surprisingly, two further miss-sense and one putative splice sitemutation have been identified, all in families with typical late onsetPD, compatible with a dominant transmission: (I1122V; 3364A>G) in family21; (I2020T; 6059T>C) in family 32, and (L1114L; 3342A>G) in family 38,which is 6 by away from the exon/intron border. Affected individuals ina further family (469) were found to carry the same mutation as family D(R1441C; 4321C>T). Those two families are not known to be related, nordid they share haplotypes for the closest flanking microsatellite repeatmarkers D12S2194, D12S1048 or three newly developed intragenic repeatmarkers, indicating that the mutations are extremely ancient or aroseindependently (for pedigree structures see FIG. 2).

Again, the mutations segregated with the disease in all families andnone of them were found in controls. Three of the amino acidsubstitutions (R1441C, Y1699C and I1122T) are additionally highlyconserved across species (see FIG. 3).

Screening the entire coding region of the KASPP/LRRK2 gene in a cohortof 53 apparently unrelated families with apparently autosomal mode ofinheritance, seven more families with amino acid substitutions or onesplice site mutation have been identified. Mutations in the KASPP/LRRK2gene, therefore, account for 13% of familiar PD in our total cohort.

In the second study four novel mutations (R793M, Q930R, S1096C andS1228T) have been identified. Therefore, together with the publishedmutation, until now, 10 missense mutations and one splice site mutationhave been described.

The KASPP/LRRK2 gene consists of 51 exons comprising five conserveddomains (see FIGS. 5 and 7) indicating that it belongs to a recentlydefined ROCO protein family (Bosgraaf L. et al. Biochim. Biophys. Acta.,1643 (1-3), 5-10, 2003).

The five conserved domains are in detail:

(1) N-terminal leucine-rich repeat (LRR) consisting of 12 strands of a22-28 amino acid motif, present in a tandem array; (2) ROC (Ras ofcomplex) domain indicating the affiliation of the protein to theRas/GTPase superfamily; (3) COR (C-terminal of Roc) domain; (4) tyrosinekinase catalytic domain (MAPKKK) and (5) C-terminal WD-40 domain.

Proteins containing LRRs are associated with diverse functions, such ashormone receptor interactions, enzyme inhibition, cell adhesion,cellular trafficking, splicing and substrate binding for ubquitination,a common property involves protein-protein interaction (Kobe B. et al.,Curr. Opin. Struct. Biol., 11(6), 725-723, 2001). In particular, theN-terminal LRR and the C-terminal WD-40 propeller structure are assemblypoints for larger protein complexes. Ras/GTPase domains are involved inthe reorganization of the actin cytoskeleton in response to externalstimuli. They also have roles in cell transformation by Ras, incytokinesis, in focal adhesion formation and in the stimulation ofstress-activated kinase (Ridley A. J. Trends Cell. Biol, 2001). Inparticular, the fusion of a Ras-like domain with a MAPKKK domainindicates the function of KASPP/LRRK2 in intramolecular signaltransduction. Furthermore, KASPP/LRRK2 should also function as ascaffolding protein like Ksr (Kinase suppressor of Ras). The KASPP/LRRK2kinase domain shows also similarity to the RIR and Mixed lineage kinaseswhich are part of the TKL-(thyrosine kinase like) branch of the humankinome indicating an involvement in stress-induced cell signalling andmediation of apoptosis. The COR domain is characteristic for thisprotein family and shows no significant sequence homology to any domainor protein today. Enzymes with a tyrosine kinase catalytic domain belongto an extensive family of proteins which share a conserved catalyticcore common to both serine/threonine and tyrosine protein kinases. Theyexert their function by catalyzing the transfer of the gamma-phosphateof ATP to tyrosine residues on protein substrates (Hubbard S. R. et al.Annu. Rev. Biochem., 69, 373-398, 2000). The WD40 domain is implicatedin signal transduction, pre-mRNA processing and cytoskeleton assembly(Smith T. F. et al., Trends Biochem. Sci., 24(5), 181-185, 1999).

In view of the present invention three Roco proteins of the Roco-proteinfamily exist now in mammals: LRRK1, DAP-kinase (death associated proteinkinase) and KASPP/LRRK2 of the present invention. The mammalianDAP-kinase, for example, should be involved in cytosceletalrearrangements and/or induction of apoptosis dependent on its activity.

The biochemical analysis of KASPP/LRRK2 and its Parkinsondisease-associated variant, I2020T, bearing a mutation located next tothe DFG motif (DYG in KASPP/LRRK2) at the beginning of the activationloop of the kinase domain which is highly conserved in almost allMAPKKK, indicates according to the present invention that KASPP/LRRK2acts as a true protein kinase at cytoskeletal and membraneous structurewithin the cell. In addition, the found increase (approximately 30-50%)in the kinase activity of the I2020T mutant is consistent with mutationsin homologous positions of other kinases like B-Raf associated withcancer (Dibb, N. J. et al. (2004), Nat. Rev. Cancer, 4, 718-727). It isalso worth to be noted that this mutation is a dominant feature. Inaddition to an overall gain in kinase activity, the mutation could alsoalter substrate specificity. As with oncogenic kinase variants, kinaseinhibitors could then be considered as a treatment option. Theeffectiveness of such therapeutic strategy has been proven with respectto specifically inhibiting the bcr-abl protein kinase within chronicmyeloic leukemia (CML) through the kinase inhibitor2-phenylaminopyrimidine STI571 (Gleevec), a small-molecule tyrosinekinase inhibitor for the treatment of CML (Chalandon, Y. & Schwaller,J., Haematologica, 90, 949-968, 2005).

In summary, the biochemical analysis of KASPP/LRRK2 and its I2020Tmutant according to the present inventions shows that KASPP/LRRK2 sharescommon features with other MAPKKK, such as autophosphorylation,dimerisation or interaction with kinase specific chaperones. Theautokinase activity of the mutant I2020T, localised within theactivation loop of the KASPP/LRRK2 kinase domain is increased whencompared to wild-type KASPP/LRRK2 according to the present invention. Inview of its multimodular structure, KASPP/LRRK2 should be involved infunctions as diverse as maintenance of microtubular ultrastructure anddynamics, vesicular trafficking (ER, Golgi compartment) and/orcytoskeletal rearrangements.

Interestingly, all ten mutations are within these conserved domains(FIG. 7). The R793M mutation, however, is located in exon 19 which ispart of the ancyrin repeat region (amino acid 678-806), that seems totake part in protein-protein interactions.

In contrast to previous reports the so far most common mutation (G2019S;6055G>A, Hernandez D G et al., Ann Neurol, 57: 453-6, 2005) was notdetected in any of the families investigated but only in one patientwith sporadic PD. Moreover, this mutation was found in only one out of340 patients with sporadic PD. Therefore, the predominance of thismutation (Gilks et al., Lancet, 365: 415-6, 2005; Toft et al., Lancet,365: 1229-30, 2005) can not be established for all populations. Thescreening in familial and sporadic PD patients showed frequencies of theG2019S mutation up to 7% in familial and almost 1% in sporadic PD cases,however, no association could be demonstrated of this mutant with thenon-mendelian sporadic form of PD in a recent study of the inventors. Inthe present cohort comprising 340 patients with sporadic PD the novelR793M was additionally found in one sporadic patient. Therefore,KASPP/LRRK2 mutations account for only 0.6% of sporadic PD cases in thepresent population.

In three families the specific variation did not cosegregate with onefamily member each: In family DE022, the Q930R only three of the fourfamily members affected by the disease were mutation carriers (FIG. 6b), in family E in fact only one of the two family members with PDphenotype was carrier of the S1096C mutation (FIG. 6 f), and the splicesite mutation cosegregating with PD in one previously investigatedfamily (DE038) was only found in one of the clinically affected sisters(T112888) (FIG. 6 c). As none of these variations was found in any ofthe 1200 controls investigated and the splice site variation affectedtwo distinct PD families it is likely that they are causative for thedisease, although incomplete penetrance at least in family DE022 couldindicate that additional factors may contribute to manifestation of thedisease in affected subjects. This may be due to phenocopies in thesethree families, as the high prevalence of PD in the population makes itwell possible that other causes of PD occur in a family affected byKASPP/LRRK2 mutations. Disease phenocopy is not uncommon in PD. It hasbeen described in the original α-synuclein A53T kindred (Polymeropouloset al., Science, 276: 2045-7, 1997), in a family with the KASPP/LRRK2G2019S mutation (Hernandez et al., 2005, supra), but also in family Dwith the KASPP/LRRK2 R1441C mutation.

Three of the present mutations affect at least two families. For two ofthese (R793M and I2020T) haplotype analysis revealed a common haplotypeindicating a common founder. None of the families was aware of apossible relation to the respective family although the two familiesharbouring the I2020T mutation lived in the same geographic region. Thesame mutation has also been described in the Japanese family, who servedas the basis for the original defining of the PARK8 locus (Funayama etal., Ann Neurol., 57: 918-21, 2005).

The R793M mutation, detected in two distinct families with the samehaplotype, was also found in one patient with sporadic PD and onecontrol person. Because of technical problems in assessing this CG richexon call rate of the population screened was low (about 50% in threedifferent tries). Therefore, it may well be, that this mutation is morefrequent in apparently sporadic PD patients. Also, the possibility of apolymorphism needs to be taken into account, if this variation wasdetected in more controls. However, finding of a possible common founderin the two families with the mutation is an indication for a diseaserelated amino-acid substitution. Common founders are also suggested forother families affected by mutations in the KASPP/LRRK2 gene (Mata etal., Neurosci Lett, 382: 309-311, 2005).

Mode of inheritance of KASPP/LRRK2 mutations is autosomal dominant. Ithas been suggested that penetrance of KASPP/LRRK2 mutations is agedependent (DiFonzo et al., Lancet, 365: 412-5, 2005; Toft et al., 2005,supra) accounting for the reduced penetrance in some families. In thepresent families reduced penetrance was only observed in mutations ofexons 19 and 21 located before the highly conserved LRR domain. Thisindicates that mutations in this region are less severe and have to beassociated with other so far unknown factors for disease manifestation.From the splice site mutation of exon 24 onwards, penetrance wascomplete, although one splice mutation carrier (DE038, III-1) had onlyslight resting tremor for several years, while his sister (III-3),mother and uncle were affected by severe PD.

In all families with definite documentation of age of onset an earlierrecognitions of first Parkinsonian signs was observed in the youngergenerations. So far, there are no known pathomechanism that allow thehypothesis of anticipation. Rather, a greater awareness of a possibleaffliction and a more thorough investigation in families in whom PD hasalready been diagnosed could account for the earlier diagnoses.

The clinical presentation of KASPP/LRRK2 mutation carriers varies withinfamilies and between families affected by the same mutation. In generalthe typical phenotype of PD with resting tremor, bradykinesia, rigidityand olfactory dysfunction can be observed. Interestingly, tremor, themain and naming feature of some of the initially described to families(Paisan-Ruiz et al., Neuron, 44: 595-600, 2004) was neither the maininitial nor the leading symptom in many of our PD patients. Two patientsdid not report any resting tremor in their medical history. Rather, thetypical pattern of different subtypes known from idiopathic PD could beobserved. All patients reported a substantial relief of symptoms afterapplication of dopaminergic treatment, which was hampered byhalluzinations in only the one patient with DLBD-phenotype (Diffuse LewyBody Disease-phenotype).

In patients with KASPP/LRRK2 mutations a frequent, the patient stronglyafflicting symptom seems to be sleeping abnormality. Eight out of 10patients (80%) reported to suffer from difficulties of either falling asleep, staying a sleep or both. According to several studies, sleepingdisturbancies occur in about 40-75% of PD patients (Lees et al., ClinNeuropharmacol., 11:512-519, 1988; Kumar et al., Mov Disord, 17:775-781, 2002), but only the minority (about 20%) reports sleepingabnormalities as a problem (Lees et al., 1988, supra). In the presentstudy 80% stated that sleeping disturbances were indeed a problem. Moredetailed assessment on sleeping behaviour and pattern are to be decided,whether this symptom is more pronounced in KASPP/LRRK2 mutationscarriers, possibly indicating an earlier involvement of the respectivesystems. Postural instability occurs late in the course of the disease.As also described by others (Paisan-Ruiz et al., Ann Neurol., 57:365-72,2005) dementia is not a common finding in KASPP/LRRK2 associated PD andseems to occur rather late in the disease process. The same holds truefor hallucinations in our patient cohort, occurring either late in thedisease process or in combination with dementia. In the present cohort,one patient presented with the typical clinical picture of DLBD. Autopsyof one subject with dementia in our first cohort revealed diffuse LewyBody pathology in one family affected by the Y1699C mutation.Description of the same phenotype in an other patient in this studyaffected by a different mutation favours the hypothesis that theclinical presentation of DLBD may be caused by the samepathophysiological alterations as the clinical picture of PD. Obviouslyspecific pathophysiological changes (in this case caused by mutations inthe KASPP/LRRK2 gene) may lead to the clinical and histopathologicalentity of both: PD and DLBD.

In our first study one patient showed mild signs of motor neurondisease. In the second study, however, motor neuron symptoms wereneither clinically nor electrophysiologically disclosed in any patientinvestigated.

Structural neuroimaging revealed slight to marked atrophy in all 4patients investigated, although disease duration was only 3-12 years inthese and only one was classified as demented (Table 4). This contrastsfindings of idiopathic PD, where structural MRI is usually normal andatrophy only occurs with disease progression, usually associated withdementia. The patient with the clinical presentation of DLBD had markedsigns of microangiopathy, which may also be causative for an atypicalParkinsonian syndrome. The clinical presentation with fluctuation ofvigilance, good response to L-dopa hampered by hypersensitivity anddementia developing over a short period of time, however, makes thediagnosis of DLBD more likely.

TCS revealed SN hyperechogenicity—the typical sign for idiopathic PD,found in more than 90% of PD patients (Berg et al., 2001, supra; Walteret al., J Neural Transm, 109:191-196, 2002)—on at least one side ofKASPP/LRRK2 mutation carriers. Interestingly, SN hyperechogenicity wasonly moderate in all patients investigated, as opposed to idiopathic PD,where it is marked in 73-79% of the patients. This highly characteristicfinding is supposed to be associated with an increase in tissue ironcontent and possible alterations in iron binding, antedating themanifestation of disease onset (Berg et al., 1999, supra: Berg et al.,Neural Transm, 109:191-196, 2002). An only moderate hyperechogenicity ofthe SN in KASPP/LRRK2 associated PD may argue for a different course ofunderlying pathomechanisms, which may finally lead to less ironaccumulation in KASPP/LRRK2 associated than in idiopathic PD. Similarly,the slower disease progress, documented by less although typicallylocated reduction of F-Dopa uptake in PET examinations (Hernandez etal., 2005, supra) favours the hypothesis of a different course of thedisease.

In conclusion, in two consecutive studies it has been shown thatKASPP/LRRK2 mutations account for about 13% of apparently autosomaldominantly inherited PD and sib pairs in the population investigated.Although the phenotype varies within and between families affected bythe same mutations it is very similar to the clinical presentation ofidiopathic PD. The causal relation between disease manifestation andvariation is not equally clear for all variations described. In threefamilies the specific variations did not co-segregate with one familymember each affected by the disease. As none of these mutations wasfound in 1200 control persons, and one variation was found in twodistinct PD families phenocopies is indicative.

Moreover, two patients with the clinical presentation of DLBD shouldlead to the consideration of KASPP/LRRK2 mutations in families with thesimultaneous occurrence of DLBD and PD.

As already pointed out above mutations have been found in differentfunctional domains but it is unclear which of them are related toneurodegeneration. However, KASPP/LRRK2 may be central to a range ofneurodegenerative processes because our findings show that (i)KASPP/LRRK2-mutations appear to be a numerically important cause ofautosomal-dominant parkinsonism (6 independent mutations in 34 familieswith dominant inheritance) and (ii) affected individuals withKASPP/LRRK2 mutations exhibit strikingly variable pathologic changes,representing aspects of several of the major neurodegenerative diseases.

Using cell fractionation and carbonate extraction the present inventiondiscloses that KASPP/LRRK2 is associated partially with mitochondria,the cytoskeleton and microsomal membranes, which is an indication thatKASPP/LRRK2 is involved in cytoskeletal rearrangements. No KASPP/LRRK2was found in the cytoplasm. Further, the autokinase activity ofKASPP/LRRK2 is not significantly changed in the disease-associatedI2020T mutant compared with wild-type, indicating that the autosomaldominant effect is caused by a toxic gain of function rather than lossof function. The I2020T mutation is located next to the conserved motifDFG (DYG in LRRK2) at the beginning of the activation segment of thekinase domain (Ross O. A. & Farrer M. J. Biochem. Soc. Trans., 33,586-590, 2005) and in the mutation a hydrophobic leucine residue isexchanged by a polar threonine residue. This is also an indication thatassociated Parkinson's disease is caused by altered substratespecificity or higher KASPP/LRRK2 activity. Homodimerization andassociation with the HSP90/p50^(cdc37) chaperone-system further indicatethat the KASPP/LRRK2 function and activation mechanisms are similar toother MAPKKK. These effects serve as a basis for the development of asuitable screening assay and/or the development of a pharmaceutical or adiagnostic agent as described below in detail.

Autopsies performed on affected individuals uniformly demonstratedneuronal loss and gliosis in the substantia nigra as the pathologicalsubstrate of parkinsonism. However, α-synuclein pathology (Lewy-bodies,LBs) typical for PD was seen only in one case from family D. In anothercase from this family widespread LB's was more consistent with diffuseLewy Body disease (DLB). Even more intriguingly, senile plaques andneurofibrillary tangles (NFTs) as well as prominent tau deposits weredemonstrated in 3 other brains from both large kindreds. Spinal cordpathology consistent with a diagnosis of amyotrophic lateral sclerosis(ALS) was found in affected members of family A.

Hence, KASPP/LRRK2 is likely to be central to the aetiology of allneurodegenerative diseases such as PD, Alzheimer disease (AD) andamyotrophic lateral sclerosis (ALS) and pathologies, includingsynucleinopathy and tauopathy, associated with a clinical phenotype ofparkinsonism.

It has previously been shown that tau and α-synuclein pathologies may beclosely linked. Tau-aggregations have been found in the brains ofpatients carrying pathogenic A53T α-synuclein mutations (Kotzbauer P. T.et al., Exp. Neurol., 187(2), 279-288, 2004; Duda J. E. et al., ActaNeuropathol. Berl., 104, 7-11, 2002) Similarly, the major pathogenicprotein aggregating in AD has been shown to promote fibrillization oftau and formation of neurofibrillary tangles in an animal model (GotzJ., Science, 293, 1491-1495, 2001). Interestingly, a genomic regionoverlapping the PARK8 locus has been identified in a linkage study offamilial Alzheimer disease (Scott W. K. et al. Am. J. Hum. Genet.,66(3), 922-932, 2000). Evidence for linkage was derived in a large partfrom families with at least one member with autopsy proven diffuse Lewybody disease. Whether this linkage result reflects variants in theKASPP/LRRK2 gene remains to be determined.

The expression pattern of KASPP/LRRK2 was subsequently examined in brainand other tissues. Human brain and multiple tissue Northern blots werehybridized with a 1078 by 3′ cDNA probe and found expression in mostbrain regions, albeit at a very low levels. Two transcripts of about 9kb and 8 kb, respectively, and multiple bands at lower sizes were found.The two transcript sizes might be explained by alternative splicingand/or the alternative use of polyadenylation sites.

As low overall expression levels in brain precluded a detailed analysisof its regional distribution by Northern blotting, real-time RT-PCR wasdone using RNA isolated from adult and fetal whole brain as well as fromdifferent brain regions in order to assess quantitative gene expressionand alternative splicing. Primers have been designed to generatespecific PCR products for exon1-8, exon13-19 and exon 31-39,respectively. Within the same tissue or brain region transcript levelsof all three assays showed no significant differences. Consistentexpression in most brain regions have been found, slightly higher inputamen, substantia nigra and heart. The highest expression levels wereobserved in lung. The cDNA analysis, within in multiple tissues,confirms in silico prediction that at least 11 exons may bealternatively spliced. In adult human brain tissue, exon 6 wasconstitutively expressed within the full length mRNA.

In view of the above, the present invention is also directed to avector, preferable an expression vector, containing the nucleic acidmolecule of the present invention, to a cell containing the nucleic acidor the vector of the present invention and to a transgenic animalcontaining the nucleic acid or the vector of the present invention.

A vector can be a plasmid or phage DNA or any other DNA sequence intowhich DNA can be inserted to be cloned. The vector can replicateautonomously in a host cell, and can be further characterized by one ora small number of endonuclease recognition sites at which such DNAsequences can be cut in a determinable fashion and into which DNA can beinserted. The vector can further contain a marker suitable for use inthe identification of cells transformed with the vector. Markers, forexample, are tetracycline resistance genes or ampicillin resistancegenes.

In a further embodiment the vector can be in the form of an expressionvector containing an expression cassette which comprises the nucleicacid molecule of the present invention, but preferably also furthercomprising expression control sequences which are operatively linked tothe nucleic acid molecule. The expression control sequences are chosenso that they allow expression of the encoded polypeptide in a host. Forexample a nucleic acid sequence encoding a polypeptide of the presentinvention can be isolated and cloned into an expression vector and thevector can then be transformed into a suitable host cell for expressionof the polypeptide of the invention. Such a vector can be a plasmid, aphagemid or a cosmid. For example, a nucleic acid molecule of theinvention can be cloned in a suitable fashion into prokaryotic oreukaryotic expression vectors, preferably into eukaryotic expressionvectors and more preferably into expression vectors allowing expressionin a mammalian and in particular in a human cell which is known to aperson skilled in the art. Such expression vectors typically comprise atleast one promoter and can also comprise a signal for translationinitiation of the reading frame encoding the polypeptide and—in the caseof prokaryotic expression vectors—a signal for translation termination,while in the case of eukaryotic expression vectors the expressioncassette preferably comprises expression signals for transcriptionaltermination and polyadenylation. Examples of suitable eukaryoticexpression vectors are well known for the person skilled in the art,e.g. for the expression in insect cells via baculovirus vectors, and forexpression in mammalian cells, e.g. the SV40 or CMV vectors, thesindbisvirus expression system, or an adenovirus expression system, aSemliki Forest Virus-based expression system, or a lentivirus-basedexpression system. The molecular biological methods for the productionof these expression vectors are also well known to the skilled person,as well as the methods for transfecting host cells and culturing suchtransfected host cells. In a preferred embodiment the above-mentionedexpression control sequences specify induced expression of thepolypeptide of the invention, that is induced transcription of themessenger RNA encoding the polypeptide of the invention upon addition orwithdrawal of an external signal, such as a small chemical liketetracycline or a hormone like Ecdysone, but the extracellular signalcan also be an increase or decrease in temperature or ionizingradiation. Also, inducible expression can be brought about by inducibletranslation initiation of the messenger RNA or a system in which mRNAstability is controlled in an inducible fashion. Examples of expressioncontrol sequences allowing induction of polypeptide production arereviewed in the following publications: the TET-off/TET-on system,suitable for both cell cultures and transgenic animals, but also theexpression control system based on Cre-recombinase based methods,predominantly for use in transgenic animals. A further inducibleexpression system, for use in both cell culture and transgenic animalsis based on the insect hormone Ecdysone. Another inducible expressionsystem is the GAL4 system, which has been successfully applied withmice, zebrafish and Drosophila, and allows conditional expression at26-29 degrees, or also a Rapamycin based conditionals expression system.A temperature-sensitive expression system is based on a Sindbis virusexpression cassette and predominantly suitable for controlled expressionin cell culture systems.

Another aspect of this invention relates to a cell comprising a nucleicacid or a vector of the present invention. Such a cell can be amammalian, non-human cell inside or outside of the animal body or ahuman cell outside of the human body. But it can also be an insect cell,like a drosophila cell, in culture or in the context of a transgenicinsect, like a transgenic Drosophila. It can also be a nematode cell,like, for example, present in transgenic C. elegans. Preferred hostcells are mammalian, and particularly human, neuronal cells, microgliacells, astrocytes, oligodendrocytes, fibroblasts, monocytes, andmacrophages and other non-neuronal primary cells, which can be kept inprimary tissue culture and can be made capable of expressing thepolypeptide of the invention by introducing the nucleic acid/or theexpression cassette of the invention, for example by transfection withsuch a nucleic acid or expression cassette. Other means of introducingthe nucleic acid and/or the expression cassette of the invention to theabove-mentioned primary cells are “gene gun” approaches, mRNA transfer,viral infection, microinjection or liposomal nucleic acid transfer, toname but a few. Other suitable host cells are mammalian cells like HEKcells, HELA cells, PC12 cells, CHO cells, JURKAT cells, mouse 3T3fibroblasts, mouse hepatoma cells, human neuroblastoma cells, but alsoestablished cancer cell lines, particularly neuronal cell lines, ofmammalian and particularly of human origin.

The nucleic acid and/or the expression cassette of the invention canalso be introduced into those cells by the above-mentioned nucleic acidtransfer methods. Particularly preferred are stably transformed celllines wherein the expression of the polypeptide of the invention isinducible. Since expression of the polypeptide of the invention may showincreased neuropathology, it may be preferred that in such host cellsthe expression of the polypeptide of the invention is usually very lowor off, for example during the generation of a stably transformed cellline, and only for experimental purposes and after establishment of sucha stably transformed cell line the expression of the polypeptide of theinvention is turned on by addition of a suitable stimulus, like e.g. ahormone like Ecdysone or a small chemical like the antibiotictetracycline. Again, the above described examples of expression controlsequences allowing induction of polypeptide production are suitable forthis purpose, like the TET-off/TET-on system, the Cre-recombinase basedmethods, the Ecdysone system, the GAL4 system, Rapamycin-based systems,or the above described temperature-sensitive expression system based ona Sindbis virus expression cassette.

Another aspect of the invention relates to transgenic animals whichcomprise a host cell of the invention. Particularly preferred aretransgenic flies, like transgenic Drosophila, transgenic nematodes, liketransgenic C elegans, transgenic fish, like transgenic zebra fish, andtransgenic non-human mammals, like transgenic rodents (mice, rats).

Meanwhile, the generation of transgenic animals are within the generalskill of a person skilled in the art. In addition, it is pointed outthat under the control of tissue-specific promoters expression could betargeted to the CNS in mice and others. Most tissue-specific topromoters could be used, for example, also in the context of viralvectors. In the following, tissue-specific promoters of rodents arelisted. Expression in astrocytes: GFAP-promoter, macrophagecolony-stimulating factor (c-fms). Expression in neurons: synapsinpromoter, thy-1 promoter, neuron-specific rat enolase promotor (NSE), L7promoter (Purkinje cells), dopamine beta-hydroxylase (DBH) promoter(predominantly in the peripheral nervous is system), brain dystrophinpromoter, calmodulin gene II and III promoter (CaMII, CaMIII), human andmurine neurofilament light gene promoter (NF-L), human hypoxanthinephosphoribosyltransferase (hHPRT) promoter, corticotropin-releasinghormone (CRH), T alpha 1 alpha-tubulin promoter, murine low-affinity NGFreceptor promoter, hippocalcin gene promoter, olfactory marker protein(OMP) promoter (olfactory neurons), GABA(A) receptor alpha 6 subunitpromoter, GABA(A) receptor delta subunit promoter, tyrosine hydroxylase(TH) promoter, mouse vesicular acetylcholine transporter (VAChT), mouseglutamate decarboxylase 65 and mouse glutamate decarboxylase 67 genespromoters, brain-specific promoter of the human FGF1,gonadotropin-releasing hormone (GnRH) promoter, N-methyl-D-aspartatereceptor 2A subunit gene promoter; mouse metabotropic glutamate receptorsubtype 6 (mGluR6) upstream sequence, Rod photoreceptor cGMPphosphodiesterase (PDE6), human blue opsin promoter and rhodopsinpromoter (retina). Neuron-restrictive silencer elements:Neuron-restrictive silencer elements (NRSEs). Expression inoligodendrocytes: MBP (myelin basic protein), proteolipid protein (PLP)promoter.

Furthermore, the present invention is directed to a protein encoded by anucleotide sequence of the present invention, in particular a proteincontaining the amino acid sequence of SEQ ID NO: 1 or 2 or at least oneof the mutations depicted in SEQ ID NO: 1 or 2, such as the mutationR793M, Q930R, S1096C, L1114L, I1122V, S1228T, R1441C, Y1699C and/orI2020T.

It is particularly pointed out that the present invention encompassesalso proteins which contain one or more amino acid substitutions in theKASPP/LRRK2 protein but still retains essentially its function. Suchamino acid substitutions may be semi-conservative or conservative andmore preferably a conservative amino acid residue exchange. In thefollowing table such amino acid substitutions are exemplified.

Conservative Semi-conservative Amino acid substitution substitution A G;S; T N; V; C C A; V; L M; I; F; G D E; N; Q A; S; T; K; R; H E D; Q; NA; S; T; K; R; H F W; Y; L; M; H I; V; A G A S; N; T; D; E; N; Q H Y; F;K; R L; M; A I V; L; M; A F; Y; W; G K R; H D; E; N; Q; S; T; A L M; I;V; A F; Y; W; H; C M L; I; V; A F; Y; W; C; N Q D; E; S; T; A; G; K; R PV; I L; A; M; W; Y; S; T; C; F Q N D; E; A; S; T; L; M; K; R R K; H N;Q; S; T; D; E; A S A; T; G; N D; E; R; K T A; S; G; N; V D; E; R; K; I VA; L; I M; T; C; N W F; Y; H L; M; I; V; C Y F; W; H L; M; I; V; C

For example, changing from A, F, H, I, L, M, P, V, W or Y to C issemi-conservative if the new cysteine remains as a free thiol.Furthermore, the skilled person knows that glycines at stericallydemanding positions should not be substituted and that P should not beintroduced into parts of the protein which have an alpha-helical or abeta-sheet structure.

The present invention is also directed to the manufacturing of theproteins by methods already explained above. In short such methodcomprises

-   (a) culturing a cell of the present invention under suitable    conditions; and-   (b) isolating the protein produced by the cultured cell.

Another preferred embodiment of the present invention is directed to amethod of detecting a mutation at position 2378, 2789, 3287, 3342, 3364,3683, 4321, 5096 and/or 6059 in the nucleic acid molecule of SEQ ID NO:1 or 2 in a sample, the method comprising:

-   (a) contacting said sample with the nucleic acid molecule according    to the present invention, and-   (b) detecting the presence of the mutation.

Preferably, the sample is selected from

-   (a) a sample, in particular a biopsy, from human tissue or cells, in    particular from the brain, in particular putamen or substantia    nigra; heart, lung and/or blood lymphocytes; Or-   (b) RNA and/or DNA from a sample, in particular a biopsy, from human    tissue or cells, in particular from the brain, in particular putamen    or substantia nigra; heart, lung and/or blood lymphocytes;

In general, the detection can be carried out by Southern blothybridization, Northern blot hybridization, PCR or RT-PCR includingreal-time RT-PCR, techniques which are well known to a person skilled inthe art. The mutation can also be detected by radiography, fluorescence,chemiluminescence, or any combination thereof. Preferably automatedsequencing can be carried out, an electrophoresis method run basicallyin a capillary (column) combined with fluorescence.

Other methods for detection and/or quantification of the amount ofpolynucleotides, i.e. for the methods according to the inventionallowing e.g. the determination of the level of expression of apolynucleotide containing a mutation, are real time methods known in theart as the TaqMan® method disclosed in WO92/02638. This method exploitsthe exonuclease activity of a polymerase to generate a signal. Indetail, the (at least one) target nucleic acid component is detected bya process comprising contacting the sample with an oligonucleotidecontaining a sequence complementary to a region of the target nucleicacid component and a labeled oligonucleotide containing a sequencecomplementary to a second region of the same target nucleic acidcomponent sequence strand, but not including the nucleic acid sequencedefined by the first oligonucleotide, to create a mixture of duplexesduring hybridization conditions, wherein the duplexes comprise thetarget nucleic acid annealed to the first oligonucleotide and to thelabeled oligonucleotide such that the 3′-end of the firstoligonucleotide is adjacent to the 5′-end of the labeledoligonucleotide. Then this mixture is treated with a template-dependentnucleic acid polymerase having a 5′ to 3′ nuclease activity underconditions sufficient to permit the 5′ to 3′ nuclease activity of thepolymerase to cleave the annealed, labeled oligonucleotide and releaselabeled fragments. The signal generated by the hydrolysis of the labeledoligonucleotide is detected and/or measured. TaqMan® technologyeliminates the need for a solid phase bound reaction complex to beformed and made detectable. Other methods include e.g. fluorescenceresonance energy transfer (FRET) between two adjacently hybridizedprobes as used in the LightCycler® format described in U.S. Pat. No.6,174,670.

A preferred protocol if the polynucleotide is in form of a transcribednucleotide is a method where total RNA is isolated, cDNA and,subsequently, cRNA is synthesized and biotin is incorporated during thetranscription reaction. The purified cRNA is applied to commerciallyavailable arrays which can be obtained e.g. from Affymetrix. Thehybridized cRNA is then detected. The arrays are produced byphotolithography or other methods known to experts skilled in the art.

Consequently, the method can be carried out on an array, e.g. in arobotics system or using microfluidics.

The present invention is also directed to a diagnostic kit containing atleast one nucleic acid molecule of the present invention for diagnosinga neuronal disease, in particular a neurodegenerative disorder,especially Parkinson Disease (PD) including, without limitation,sporadic PD, Alzheimer Disease (AD), amyotrophic lateral sclerosis(ALS), synucleinopathy and/or tauopathy, in combination with suitableauxiliaries. Suitable auxiliaries, as used herein, include buffers,enzymes, labelling compounds, and the like. In a preferred embodiment,the nucleic acid molecule contained in the kit is a nucleic acidmolecule which is capable of hybridizing to the mRNA corresponding to atleast one nucleic acid molecule of the present invention. Preferably,the nucleic acid molecule is attached to a solid support, e.g. apolystyrene microtiter dish, nitrocellulose membrane, glass surface orto non-immobilized particles in solution. Alternatively, the diagnostickit contains one or more means necessary for automated sequencing.

The present invention refers also to a pharmaceutical containing atleast one nucleic acid molecule or a protein of the present inventionwhich can be used for the prevention or treatment of a neurodegenerativedisorder, especially Parkinson disease including, without limitation,sporadic PD, AD, amyotrophic lateral sclerosis (ALS), synucleinopathyand/or tauopathy. Therefore, the nucleic acid molecule or protein of thepresent invention can also be used for the preparation of a medicamentfor treating a neurodegenerative disorder as e.g. exemplified above.

Another embodiment of the present invention is directed to a method forscreening a pharmaceutical or diagnostic agent, the method comprising:

-   (a) providing at least one nucleic acid molecule or a protein of the    present invention,-   (b) providing a test compound, and-   (c) measuring or detecting the influence of the test compound on the    expression activity of the nucleic acid molecule or the protein.

For example, the test compound is provided in the form of a chemicalcompound library. According to the present invention the term “chemicalcompound library” refers to a plurality of chemical compounds that havebeen assembled from any of multiple sources, including chemicallysynthesized molecules and natural products, or that have been generatedby combinatorial chemistry techniques.

The influence of the test compound can be measured or detected in aheterogeneous or homogeneous assay. As used herein, a heterogeneousassay is an assay which includes one or more washing steps, whereas in ahomogeneous assay such washing steps are not necessary. The reagents andcompounds are only mixed and measured. Heterogeneous assays are, forexample, ELISA, DELFIA, SPA and flashplate assays. Alternativehomogeneous assays are, for example, TR-FRET, FP, ALPHA and gene assays.

The method can also be carried out on an array or using whole cells, e.g. in a robotics system or using microfluidics.

Methods for preparing such arrays using solid phase chemistry andphotolabile protecting groups are disclosed, for example, in U.S. Pat.No. 5,744,305. These arrays can also be brought into contact with testcompound or compound libraries and tested for interaction, for examplebinding or changing conformation.

Whole cells usually grow at the bottom of multiwell plates and are fixedand permeabilized, blocked and incubated with e.g. a primary(P)-specific antibody against the substrate of interest. Then, e.g.Europium labelled or HRP conjugated secondary antibodies in conjunctionwith specific chemiluminescent or colorimetric substances, e.g. asdescribed above, are utilized to generate the signal. In combinationwith the use of a microscope not only the amount of (P)-specificantibodies can be quantified on the single cell level, but alsophosphorylation-induced translocations of a substrate or morphologicalchanges of the cells.

The method can also be carried out in form of a high-through putscreening system. In such a system advantageously the screening methodis automated and miniaturized, in particular it uses miniaturized wellsand microfluidics controlled by a roboter.

An example for a pharmaceutical or diagnostic agent which can be foundby the screening assay of the present invention is an antibody orantibody derivative specifically binding a protein of the presentinvention.

Therefore, the present invention is also directed to an antibody orantibody derivative which specifically binds a protein of the presentinvention.

The antibody is either polyclonal or monoclonal, preferably it is amonoclonal antibody. The term antibody derivative is understood as alsomeaning antigen-binding parts of the inventive antibody, prepared bygenetic engineering and optionally modified antibodies, such as, forexample, chimeric antibodies, humanized antibodies, multifunctionalantibodies, bi- or oligospecific antibodies, single-stranded antibodies,F(ab) or F(ab)₂ fragments, which are all well known for a person skilledin the art.

The antibodies of the present invention can also be produced byimmunization of a mammal with an immunogenic peptide and/orrecombinantly using standard protocols. A particularly preferredimmunogenic peptide is the peptide with the amino acid sequence“CRMGIKTSEG TPGFRAPEVA RGNVIYNQQA D” (SEQ ID NO:3) because it representsthe kinase domain of KASPP/LRRK2 (amino acids Nos. 2025-2055) and showshomology between mouse and human of 100%.

The antibodies and antibody derivatives of the present invention can beused e.g. for the diagnosis and/or prevention and/or treatment of aneuronal disease, in particular a neurodegenerative disorder, especiallyParkinson disease (PD) including, without limitation, sporadic PD,Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS),synucleinopathy and/or tauopathy, but also for the identification ofother pharmacologically active substances. Particular uses of theantibodies and/or antibody derivatives of the present invention are e.g.in Western blots, immuno precipitation, immuno fluorescence or ELISA.

The invention will now be further illustrated below with the aid of theFigures, Tables, Sequence Listings and Examples, without beingrestricted hereto.

DESCRIPTION OF THE TABLES, THE SEQUENCES AND THE FIGURES

-   Table 1 shows the 29 genes and its sources which have been sequenced    in the candidate region D12S1692-D12S85. “KASPP/LRRK2” is the    abbreviation of the new gene of the present invention.-   Table 2 shows primer sequences for haplotype analysis of the second    study consisting of two flanking and three intragenic markers.-   Table 3 shows the frequency of the mutations of the second study.    Mutational screening was performed in 53 PD families additional to    the 34 families of the first study, 337 patients with sporadic PD    and 1200 matched controls.-   Table 4 shows the clinical and neuroimaging features of affected    members of the families of the second study. Not all subjects could    be investigated with the same methods, which is indicated with nd    (not done). No change in comparison with normal is indicated with na    (no alteration). y year, ˜ongoing at the time of examination, B    bradykinesia, R rigidity, RT resting tremor. For brief evaluation of    olfaction a sniffing test consisting of 8 different odours (/8) was    used.-   Table 5 shows the neuropsychological assessment of the second study.    Tests applied for intelligence (LPS-K), executive function (Tower of    London), interference (CWIT), dementia CERAD 1-8; concentration (D2)    as well as mood (BDI) and quality of life (PDQ-39. ↓ performance    below, ˜average and I above average of matched healthy controls.-   SEQ ID NO: 1 shows the nucleotide sequence and the amino acid    sequence of a KASPP/LRRK2 including the sites of the particular    mutations found in the specified families (bold face).-   SEQ ID NO: 2 shows the nucleotide sequence and the amino acid    sequence of human KASSP/LRRK2 including the sites of the particular    mutations found in the specified families (bold face).-   SEQ ID NO: 3 shows the amino acid sequence of the peptide used for    the production of monoclonal antibodies against KASSP/LRRK2.-   SEQ ID NO: 4 shows the relevant section of the amino acid sequence    of the S212L polymorphism of human KASSP/LRRK2. The variation is    shown in bold face.-   SEQ ID NO: 5 shows the relevant section of the nucleic acid sequence    of the c634t polymorphism of human KASSP/LRRK2. The variation is    shown in bold face.-   SEQ ID NO: 6 shows the relevant section of the amino acid sequence    of the M2397T polymorphism of human KASSP/LRRK2. The variation is    shown in bold face.-   SEQ ID NO: 7 shows the relevant section of the amino acid sequence    of the t7190c polymorphism of human KASSP/LRRK2. The variation is    shown in bold face.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the pedigree structure of the two largest families: A(German-Canadian), D (Western Nebraska) and with mutations. Blackenedsymbols denote affected family members; asterisks (*): individuals typedfor the mutation, m: mutation carrier and wt: wildtype. To protect theconfidentiality of these results, the genotypes of some unaffectedindividuals of families A and D are not shown.

FIG. 2 shows pedigree structure of smaller families with mutations.Blackened symbols denote affected family members; asterisks (*):individuals typed for the mutation, m: mutation carrier and wt:wildtype. To protect the confidentiality of these results, the genotypesof some unaffected individuals of family 469 are not shown.

FIG. 3 shows the three across species highly conserved amino acidsubstitutions R1441C, Y1699C and I1122T (SEQ ID NOs:21-39).

FIGS. 4A-4K show the nucleotide (SEQ ID NO:20) and amino acid sequence(SEQ ID NO:8) of KASPP/LRRK2 as well as the location of the exons 1-51.The vertical lines mark the last and the first nucleotides of the exon,respectively.

FIGS. 5A-5C show A: exon positions; B: schematic drawing of KASPP/LRRK2with domains, primer positions for cDNA amplification and positions ofmutations; and C: Protein alignment of three mutations conserved amonghs: Homo sapiens (SEQ ID NOs:40, 45, and 50), mm: Mus musculus (SEQ IDNOs:41, 46, and 51), rn: Rattus norvegicus (SEQ ID NOs:42, 47, and 52),ce: C. elegans (SEQ ID NOs:43, 48, and 53) and dm: Drosophilamelanogaster (SEQ ID NOs:44, 49, and 54).

FIGS. 6A-6F show pedigree structures of families with KASPP/LRRK2mutation. Except for family DE038 which is shown to demonstratecosegregation in the first family investigated and DE032 (FIG. 6E),which is displayed to demonstrate the same haplotypes in the twofamilies affected by the I2020T mutation, all pedigrees display novelfamilies.

Blackend symbols denote family members with the clinical presentation ofPD; “+” denotes a genotyped individual, with “M” for mutation carriersand “wt” for wild-type KASPP/LRRK2. The dotted symbols in FIG. 6F denotefamily members with the clinical presentation of tremor. To protectconfidentiality the genotype of some unaffected family members are notshown. Moreover, the gender of individuals in the youngest generation offamily E is disguised.

FIGS. 7A and 7B show A; exon positions; and B: schematic drawing ofKASPP/LRRK2 with domains and positions of mutations.

FIG. 8 shows the autophosphorylation of wild type and mutatedKASPP/LRRK2. In the upper panel an autoradiogram of an SDS-PAGE blottedonto PVDF membranes is shown. γ-³²P-ATP incorporation (1 h) intoKASPP/LRRK2 wildtype and I2020T mutant is visualized using aphosphoimaging system. A loading control by immunoblotting with antiFLAG M2 is shown in the lower panel. All samples shown are form the sameexperiment and were separated on the same gel.

FIGS. 9 (A) shows a scheme of the KASPP/LRRK2-domain structure and theused Tag-fusion constructs of LRRK2.

-   -   (B) shows SDS gel separation of associated proteins co-isolated        by tandem affinity purification of KASPP/LRRK2-kinase domain        (lane 1) and a vector control (lane 2). The proteins were        visualized by colloidal coomassie staining.    -   (C) shows coimmuno-precipitation. Two FLAG tagged LRRK2-baits        (full-length and kinase domain) were tested for interaction with        HA tagged full length KASPP/LRRK2. The co-precipitated HA-tagged        KASPP/LRRK2 was visualized by immuno-blotting (3F10 anti HA,        upper panel). A loading control for the bait-constructs is shown        in the lower panel (immuno-blot: anti Flag M2). FIG. 15 (B) is        the same figure as FIG. 9 (C) in a better shape.

FIG. 10 shows the immunofluorescence of different cell structures.

FIG. 11 (A) shows cell fractionation of HEK293 cells over expressingKASPP/LRRK2-Flag. The different pellet fractions 700×g pellet (cellpellet), the 10.000×g pellet (10K pellet), 160.000×g pellet (160Kpellet) and the cytosolic fraction (160K supernatant) are shown. Thelocalization of LRRK2-Flag is shown in the first lane. The localizationof specific markers for the cytoskeleton (beta-tubulin), mitochondrialmembranes (Tom20) and the endoplasmic reticulum membrane (Sec61-alpha)are shown below.

-   -   (B) shows carbonate extraction of the 160K pellet fraction. The        starting material is shown in column 1, the pellet fraction in        column 2 and the supernatant fraction in column 3. LRRK2-flag is        shown in the first lane. For quality control of the extraction,        immuno-blots for several ER-marker proteins have been provided:        a luminal ER marker (BiP/GRP78, a 78 kD glucose regulated        protein), a peripheral cytosolic ER-associated marker (p97, VCP)        and an integral ER membrane marker (Sec61-alpha).

FIG. 12 (A) shows a further overview of KASPP/LRRK2-domain structure andconstructs. The kinase domain of human KASPP/LRRK2 (1), the full-lengthLRRK2 (2) and a disease associated LRRK2 mutant 12020T (3) were clonedin frame into a modified pcDNA3.0, containing a C-terminal affinity tag.The I2020T mutation is localised, as marked, in the kinase domain ofKASPP/LRRK2. Additionally, wild-type KASPP/LRRK2 was C-terminally taggedwith a Hemagglutinin (HA) epitope (4) and a GFP (green fluorescentprotein)-tag (5).

-   -   (B) shows LRRK2-tag and LRRK2 I2020T-tag constructs expressing        an approximately 280 kD protein in HEK293 cells, visualised by        Western-blotting after SDS-PAGE.

FIG. 13 shows KASPP/LRRK2 appearing in the particulate fractions uponsubcellular fractionation and is associated with membranes.

-   -   (A) shows KASPP/LRRK2 co-sediments with membranes. HEK293 cells        were fractionated into a cell pellet (700×g) an organelle pellet        (10K pellet), a soluble cytosolic fraction (cytosol) and a        microsomal fraction (160 k pellet). The fractions were analysed        by SDS-PAGE and Western blotting with antibodies against the        Flag-tag, TOM20 (mitochondria), PMP70, (peroxisomes), BiP/GRP78,        (ER lumen), Sec61α (ER membrane), p50^(cdc37) (cytosol) and        β-tubulin (microtubules).    -   (B) shows an alkaline extraction of KASPP/LRRK2. The 160K pellet        was treated with 100 mM sodium carbonate. Membrane and soluble        fraction (pellet and supernatant, respectively) were separated        by centrifugation and analysed as in (A) using antibodies        against the integral ER membrane protein Sec61α, the cytosolic        ER-associated protein p97/VCP and the luminal ER protein        BiP/GRP78.

FIG. 14 shows that KASPP/LRRK2-GFP localises to mitochondria,endoplasmic KASPP/LRRK2-GFP (GFP fluorescence shown in the middle panel)were immunostained for a) mitochondria (TOM20), b) endoplasmic reticulum(PDI), c) Golgi (58K Golgi) d) peroxisomes (PMP70), e) intermediatefilaments (vimentin), f) microtubular cytoskeleton (β-tubulin) and g)Phalloidin-Tritc (actin cytoskeleton). The right panel depicts digitallymerged images taken from the same micrograph section and merges greenfluorescence (GFP), red alexa 568 staining (specific markers) andnuclear staining with DAPI.

FIG. 15 shows that KASPP/LRRK2 dimerises and interacts with HSP90 andp50^(cdc37).

-   -   (A) shows co-purification of differently tagged        KASPP/LRRK2-constructs: HA-tagged full-length KASPP/LRRK2 was        tested for its ability to interact with two different tagged        KASPP/LRRK2 baits (a full-length and a kinase domain only        construct). The constructs were co-expressed transiently in        HEK293 cells prior to cell-lysis and purification. The result of        the co-purification of HA-tagged KASPP/LRRK2 with the        Step/Flag-tagged baits is shown in the upper left panel        (pellet). The co-precipitated HA-tagged KASPP/LRRK2 was        visualised by Western blotting (3F10 anti-HA).    -   (B) is the same figure as as FIG. 9 (C) in a better shape.    -   Controls: In order to demonstrate equal expression of        KASPP/LRRK2-HA a Western blot (anti-HA) of the supernatants is        shown (upper right panel). An equal loading of purified        bait-proteins was ensured by Western blotting (anti-tag, lower        left panel). Purification efficiency of Strep/Flag-tagged baits        was determined by Western blotting of the depleted supernatants:        after their affinity binding to the beads, no detectable bait        protein remains in the supernatants (lower right panel).

FIG. 16 shows western blots of HEK293 cells with different hybridomasupernatants. The first western blot shows the result of a lysate ofHEK293 cells which overexpress KASPP/LRRK2 (named “LRRK2”). The otherwestern blot shows the result of a lysate of HEK293 cells transfectedwith an empty vector (named “vector”).

FIGS. 17A-17K show the nucleotide sequence (SEQ ID NO:1) and the aminoacid sequence (SEQ ID NO:8) of a KASPP/LRRK2 including the sites of theparticular mutations found in the specified families (bold face).

FIGS. 18A-18K show the nucleotide sequence (SEQ ID NO:2) and the aminoacid sequence (SEQ ID NO:9) of a KASPP/LRRK2 including the sites of theparticular mutations found in the specified families (bold face).

FIG. 19 shows the amino acid sequence of the peptide used for theproduction of monoclonal antibodies against KASSP/LRRK2 (SEQ ID NO:3),the relevant section of the amino acid sequence of the S212Lpolymorphism of human KASSP/LRRK2 (variation shown in bold; SEQ IDNO:4), the relevant section of the nucleic acid sequence of the c634tpolymorphism of human KASSP/LRRK2 (variation shown in bold; SEQ IDNO:5), the relevant section of the amino acid sequence of the M2397Tpolymorphism of human KASSP/LRRK2 (variation shown in bold;

SEQ ID NO:6), and the relevant section of the amino acid sequence of thet7190c polymorphism of human KASSP/LRRK2 (variation shown in bold; SEQID NO:7).

Clones:

 1) 4E1  2) 4A11  3) 3G3  4) 7F1  5) 2H8  6) 2D7  7) 4A8  8) 2B5  9)4G11 10) 3G6 11) 4G11 12) 3D9 13) 4H11 14) 4F12 15) 4B7.

EXAMPLES OF THE FIRST STUDY Example 1 Genetic Analysis

DNA Extraction

Genomic DNA from peripheral blood lymphocytes was extracted usingstandard protocols and after obtaining informant's consent from allparticipating family members.

Sequence Analysis

Genomic sequences and annotations were obtained from the National centerfor Biotechnology Information (NCBI) and University of California SantaCruz (UCSC). Primers for mutation screening were designed using Primer3software integrated into script to allow for automated primer design.Exon sequences and exon-intron boundaries were amplified with intronicprimers and sequenced them directly by BigDye Terminator Cyclesequencing kit (Applied Biosystems). Between Markers D12S1692 and D12S85a total of 29 genes or RNAs were sequenced (see Table 1).

Haplotype analysis

Haplotypes were constructed by hand using the repeat markers previouslyused for linkage analysis (Zimprich, A. et al., 2004, supra). Intragenicmarkers for haplotype analysis for fam 469 and fam D were established bysearching the whole gene for repeat polymorphisms by use of a “tandemrepeat finding program” (http://c3.biomath.mssm.edu/trf.html).Polymorphic repeats were found in intron 5 (caa), intron 20 (atct) andintron 29 (ac).

Linkage analysis

Twopoint LOD scores were calculated using the MLINK program (V 5.10) inits FASTLINK implementation (V4.1P). Phenocopy rate was set at 0.01,penetrance for the heterozygous state and homozygous mutation carriersat 0.90. The allele frequency of the disease causing allele was set at0.001, as was the frequency of the mutation used as the marker.

Screening of Mutations and Polymorphisms

For mutations 2000, for polymorphisms at least 1200 control chromosomesfrom a mixed European descent were screened as controls. In addition 300patients were screened with sporadic parkinson's disease. Genotyping wasperformed on a MALDI-TOF mass-spectrometer (Sequenom MassArray system)using the homogeneous mass-extension (hME) process for producing primerextension products (Tang K. et al., Proc. Natl. Acad. Sci USA, 96,10016-10020, 1999).

Amplifikation of KASPP/LRRK2

The complete coding sequence of KASPP/LRRK2 was amplified from humanbrain cDNA by using Marathon-Ready cDNA (BD Biosciences Clontech).Primers were set to amplify three overlapping fragments from exon1-21(P1f, P1r), from exon 20-35 (p2f, p2r) and exon 34-51 (p3f, p3r) (seeFIG. 5). Sequence information were derived from published the mRNA ofDKFZp434H211. PCR products were run on agarose gel to check its lengthand integrity.

Example 2 Northern blot Analysis

Northern blot analysis was performed according to the manufacturersprotocols (BD Biosciences). For hybridization a KASPP/LRRK2 cDNAfragment was used (bp 6577-7655; corresponding to exon 45-3′UTR.

Example 3 LightCycler Experiments

mRNAs from different human tissues were purchased from BD Biosciences,(Clontech BD Sciences, Palo Alto, USA) and were reverse transcribed withthe Transciptor First Strand cDNA Synthesis Kit (Roche Applied Sciences,Mannheim, Germany) according to the manufacturers protocol. Forreal-time amplification of KASPP/LRRK2 three specific PCR productsspanning exon1 to 8, exon13 to 19 and exon 31 to 39 were quantifiedusing the

LightCycler Instrument (Roche Applied Sciences, Mannheim, Germany).Fluorescence-labeled hybridization probes providing maximum specificitywere used for product detection. Calculation of sample concentrationswere performed using the fit-point algorithm. The Phorphobilinogendeaminase (h-PBGD) gene, a low-copy housekeeping to gene, was used as anexternal standard and absolutely quantified using the (h-PBGDHousekeeping Gene Set, Roche-Applied Science). Relative transcriptlevels were calculated as ratios of Park8/PBGD normalized to adult wholebrain adult expression as 100%

EXAMPLES OF THE SECOND STUDY Subjects and Methods

Subjects

DNA of 51 index patients from PD families compatible with an autosomaldominant mode of inheritance of PD or with a mode of inheritance thatcould not be assigned to a typical Mendelian trait, as well as twoaffected sib pairs were analyzed for mutations in the KASPP/LRRK2 gene.Clinical diagnosis was based on published criteria (Hughes et al., JNeurol Neurosurg Psychiatry; 55:181-4, 1992) and severity of the diseasewas rated according to the Unified Parkinson's Disease Rating Scale(UPDRS) (Fahn et al., Recent Developments in Parkinson's Disease. NewYork: Macmillan,153-163, 1987) and Hoehn and Yahr staging. In one family(family E) typical Parkinsonian features were only found in one member(III-11), while all other affected family members presented primarilywith postural tremor. Moreover, all novel and known mutations wereinvestigated in a cohort of 337 patients with apparently sporadic PD(204 male, 133 female, mean age 53±13 years) and a cohort of 1200subjects without any extrapyramidal disorders matched for age±5 yearsand sex. Allele frequency of the polymorphism N551K; 1653C>G wasinvestigated in 888 of these control subjects.

DNA of patients with familial and sporadic PD was obtained from our genebank, while DNA of control subjects comprised the Kora cohort obtainedform the National Research Center of Environment and Health/Munich,Germany. All patients and controls had given informed consent tomutational screenings, which was approved by the local ethicalcommittee.

Mutational Screening

Genomic DNA was isolated from peripheral blood using standard protocols.Mutational screening in patients of families with autosomal dominant PDwas performed for all exons and exon-intron boundaries of theKASPP/LRRK2 gene by direct sequencing of both strands using the BigDyeTerminator Cycle sequencing kit (Applied Biosystems) with the sameprimers and under the same condition as described above.

Mutational screening in patients with sporadic PD and control subjectswas performed using an ABI 7900 Allelic Detection system. As describedabove genotyping was performed on a MALDI-TOF mass-spectrometer(Sequenom Mass Array system) using the homogeneous mass-extension (hME)process for producing primer extension products.

In families with identical mutations haplotype analysis of theKASPP/LRRK2 region was performed. Haplotypes were constructed using 5fluorescent-labeled microsatellite markers, two flanking and threeintragenic (Table 2). DNA fragments containing the polymorphic markersequences were amplified by PCR. Fluorescently labelled PCR productswere analyzed on an ABI 3100 automated sequencer with a fluorescencedetection system.

DNA extraction from Brain Tissue

In the large family with only one patient with the clinical picture ofPD and many others affected by symptoms resembling essential tremor(family E), blood for DNA extraction was only available of the PDpatient. To disclose a possible association of a KASPP/LRRK2 mutationand clinical features of essential tremor DNA was extracted from amicroscope slide with paraffin-embedded brain tissue (cerebellum) of onefamily member with this phenotype (III-7).

Deparaffinisation was performed using xylene and ethanol followed by aproteinase K digestion. The probe was then purified usingphenol/chloroform extraction and finally precipitated with LiCl andEthanol.

Clinical Investigations

The index patients of families with mutations in the KASPP/LRRK2 genewere invited for a genetic consultation and clinical and neuroimaginginvestigations under an approved protocol. After informed consent wasgiven a thorough neurological examination was performed and olfactoryfunction was tested using sniffing sticks (Daum et al., Nervenarzt,71:643-50, 2000). A neuropsychological test battery sensitive fordementia, concentration, planning, as well as intelligence was chosen(Table 5). To evaluate mood and sensitivity patients were asked tocomplete the Becks Depressions Inventar (BDI) and the PDQ-39 Parkinson'sDisease Quality of Life Questionaire.

Electrophysiological investigations comprised neurography of the righttibial and sural nerve, and elektromyography of the quadriceps todiscern subclinical changes in motor unit potentials and possibleabnormal spontaneous activity. Moreover, magnet evoked potentials wereperformed in all patients without contraindications.

Neuroimaging

Structural neuroimaging comprised transcranial ultrasound (TCS) andmagnet resonance imaging (MRI).

For TCS a phased-array ultrasound system equipped with a 2.5-MHztransducer with an axial resolution of approximately 0.7 mm and alateral resolution of about 3 mm (Elegra, Siemens, Erlangen, Germany)was used. The examination was performed through a preauricular acousticbone window with a penetration depth of 16 cm and a dynamic range of 45dB as described previously (Berg et al., Ultrasound Med Biol, 25:901-904, 1999). The SN was identified within the butterfly-shapedstructure of the mesencephalic brainstem as clearly as possible,scanning from both temporal bone windows, then the area ofhyperechogenic signals in the SN-region was encircled and measured (Berget al., 1999, supra, Berg et al., J Neurol, 248:684-689, 2001). An areaof SN hyperechogenicity ≦0.19 cm² was classified as normal, anarea >0.19 and ≦0.24 cm² as moderately and an are of >0.24 cm² asmarkedly hyperechogenic (Berg et al., 1999, supra).

MRI was performed on a Magnetom Avanto 1.5 Tesla, Siemens AG, Germany.

Results

Mutational Screening

Screening the entire coding region of the KASPP/LRRK2 gene of one indexpatient each from 55 families identified 7 novel families with aminoacid substitutions (FIG. 6 a-f). Four of these are novel missensemutations: R793M; 2378G>T in family DE041 and to family T11239, Q930R;2789A>G in family DE022; S1096C; 3287C>G in family E and S1228T; 3683G>Cin family DE031. The missense mutation R793M was also found in onepatient with sporadic PD and one control person.

The so far most common amino acid substitution G2019S; 6055G>A was onlyfound in one sporadic PD patient, who showed typical levodopa responsiveParkinson's disease with an age of onset of XX and no additionalclinical features. Moreover one additional patient was detected with thealready above described splice site mutation 3342A>G (family T11288) andone more family with the above described 12020T mutation (familyT10738).

Except for the R793M mutation, which was found in one control personnone of the mutations were found in the control group (Table 3). Therewas no significant difference in the minor allele frequency of the knownN551K; 1653C>G polymorphism between patients with sporadic PD (6.5%) andcontrol subjects (7.3%).

Haplotype Analysis

Haplotype analysis revealed common haplotypes for the two novel familiesaffected by the R793M mutation as well as for family T10758 and familyDE032 affected by the I2020T mutation, indicating common founders forthese mutations (FIGS. 6 a and 6 e). Although members of family DE032and T10758 were not aware of common ancestors, they originate from thesame geographical area (Baden Wurttemberg, Southern Germany).

Family T11239 and DE041 were recruited from more distinct geographicalareas (Baden Württemberg family T11239 and Hesse family DE041). Membersof these families were also not aware of common ancestors. For theA3342G splice site mutation no common haploptype was found in theaffected families (DE038 and T11288).

Clinical Findings

Extensive clinical a neuroimaging examination revealed the featureslisted in Table 4.

All patients investigated had typical signs of Parkinson's disease.However, features differed between members within the same familyaffected by the same mutation as well as between different families withthe same mutation. Moreover, penetrance was found to vary for differentmutations.

Common Findings in Patients with KASPP/LRRK2 Mutations

All mutation carriers with clinically apparent PD had the typicalParkinsonian features including bradykinesia, tremor and rigidity.Moreover, all patients experienced substantial relief of symptoms afterapplication of L-dopa, although therapy was complicated in one patient(T11288 II-5) by hallucinations. Estimation of olfactory function byapplication of 8 sniffing sticks revealed a moderate to severe loss ofidentification capacity in three of 5 subjects. Postural instability wasonly found late in the disease course. Hallucinations were reportedseldom and only occurred after long disease duration or associated withdementia, whereas sleep disturbances were reported by 80% (Table 4).

Intrafamily Differences in Clinical Presentation

R793M: Two sisters are affected with a difference of age of onset of 15years. While at disease onset II-1 had only slight postural tremor onthe right side, the initial symptom of II-2 was resting tremor on theleft side. An equivalent type of PD developed in II-2 while II-1 showedno resting tremor at all but an akinetic-rigid type of PD (FIG. 6 a).

Q930R: Span of age of onset was 21 years among the three members of thesame generation affected. Only brother III-7 developed severe dementiaand hallucinations after more than 20 years of disease duration (FIG. 6b).

3342A>G: While sister II-7 of family T11288 presented with typicalParkinsonian features, the clinical picture of early severe dementia,hypersensitivity to dopaminergic halluzinations and daytime sleepinesswith fluctuation of vigilance resembled DLBD in II-5. However,mutational analysis revealed the wt allele in II-7. A phenocopy for themore typical PD presentation must therefore be postulated, while theatypical DLBD-type was indeed associated with the 3342A>G splice sitemutation. However, the fact that this variation co-segregated with themutation in the above described family DE038 is an indication for amutation rather than a benign polymorphism.

Interfamily Differences in Clinical Presentation for the Same Mutation

R793M: While in III-3 of family T11239 speaking was impossible becauseof severe tongue dyskinesia, the affected sisters of family 41 did notshow any atypical signs except of postural tremor in II-1 (FIG. 6 a).

3342A>G: In family T11288 both sisters and in the reported family DE038father and III-1 were severely affected by the disease. III-3, however,did not show any Parkinsonian symptoms except of minimal resting tremorof the right thumb for more than 15 years (FIG. 6 c).

Age of Onset

Mean age of onset in the novel families was 58±14 years. However, age ofonset differed between members of the same family. In offsprings ofmutation carriers of the three novel families, in whom clear data ofancestors was available (Table 4) the diagnosis if PD was establishedearlier and also investigation of an additional family member in familyDE032 revealed and earlier diagnosis (41 years), while mean age of onsetwas 54 (48-59 years) in generation I-III (FIG. 6 e).

Penetrance

Combining findings of the second study and the first study a clearautosomal dominant mode of inheritance was found in at least oneaffected family for the splice site mutation of exon 24, and for themissense mutations of exon 25, exon 27, exon 31, and exon 41. No stronggenetic pattern was found in families affected by missense mutations inexon 19, 21 and 24.

Exon 19; R793M: In family T11239 only the uncle of the index patient wasaffected, while the father who died at the age of 68 did no show anyextrapyramidal sign during life time. In family DE041 two sisters showedtypical signs of PD during life time, while none of the parents who diedboth at the age of 74 showed any Parkinsonian signs (FIG. 6 a).

Exon 21, Q930R: Of nine sisters and brothers in family DE022 three wereaffected by the mutation and had clinical signs of PD, while one othersister and brother, also mutation carrier are not affected by PD at anage of more than 70 years. Neither the mother (II-3), who died at theage of 90 years nor her brother (II-2), who died at 75 years of ageshowed any Parkinsonian features during life time. The cousin of theaffected members of the to family (III-4) displayed signs for typical PDbut was not carrier for the Q930R mutation, indicating sporadic PD inthis family member. However, her sister (III-3), was found to have themutation. Having already reached the age of 77, she has no clinicalsigns allowing the diagnosis of PD. Both II-3 and II-2 must have beenmutation carriers. The fact that none of them and also III-3 have notshown any Parkinsonian features during life time argues for incompletepenetrance of this mutation.

Exon 24, S1096C: In this large family with an additional tremorphenotype (1f) only III-12 was mutation carrier, affected by PD. Onechild of his brother, who showed only features of essential tremor butno Parkinsonian symptoms until death at the age of 66 years, is alsomutation carrier, indicating incomplete penetrance for this mutation aswell.

Phenocopies and Simultaneous Occurrence of Tremor

One family member with typical PD of DE022, associated with the Q930Rmutation and one of the sisters of family T11288, (A3342G splice sitemutation of the other sister), again with typical Parkinsonian featureshad wt alleles, arguing for idiopathic PD in these cases.

In family E an autosomal dominant inheritance of tremor is evident (FIG.6 f). Two family members (III-7 and III-11) showed typical Parkinsonianfeatures during life time, in III-11 the S1096C mutation was detected.As there was no blood available of III-7, DNA extracted from braintissue was investigated. However, in this patient the C3287G mutationcould not be detected, indicating a different cause for Parkinson'sdisease. Of one of the siblings with a tremor phenotype (III-19,presenting with postural and vocal tremor) also only wild type allelescould be identified. The only family member with a tremor phenotypecarrying the S1096C mutation must have been the brother of III-12, asone of his children is also mutation carrier. However, as the mutationcould not be detected in III-19 incomplete penetrance of Parkinsoniansymptomes in a subject also affected by tremor is more likely than anassociation of tremor with the mutation in this family.

Neuropsychological Findings

Of the 5 patients examined in a thorough neuropsychologicalinvestigation, three were able to complete the whole test battery. Inall three intelligence was above average of a matched control group(LPS-K), suggesting that subtle neuropsychological deficits may well becompensated. Still, all three showed deficits in executive functions(Tower of London) and had high interference scores (CWIT) indicatingincapacity to blind overstimulation (Table 5). This pattern is inaccordance with neuropsychological deficits in idiopathic PD. The twoothers investigated were graded as demented. In patient III-3 of familyT11239 MMSE was 22. Additionally, severe tongue dystonia preventedaccomplishing the CERAD. In patient II-5 of family T11288 with 3342A>Gsplice site mutation exhaustability and dementia thwarted completing ofneuropsychological testing.

TCS and MRI Findings

TCS: Moderate hyperechogenicity, at least on one side, was found in allbut one patient with LRRK2 mutations. Interestingly, none of thepatients displayed marked SN hyperechogenicity. MRI showed mild tomarked atrophy in the 4 patients investigated (Table 4). The patientwith the DLBD phenotype had additionally some evidence formicroangiopathy.

BIOCHEMICAL CHARACTERIZATION OF KASPP/LRRK2 Material and Methods

Plasmid and Cloning

Human KASPP/LRRK2 was cloned via PCR from cDNA which has been generatedfrom lymphoblast mRNA. KASPP/LRRK2 was cloned domain-wise in sixfragments. Each fragment was cloned into pcDNA3.0 (Invitrogen) andverified by sequencing. The full length sequence was generated bysubsequent fusion of the sub-constructs. The HA and FLAG tag wereintroduced at the 3′ end (c-terminus) of the constructs. The I2020Tmutation was introduced into KASPP/LRRK2 by site-directed mutagenesisusing the QuikChange® II mutagenesis kit (Stratagene). For fluorescencemicroscopy, humanised GFP cDNA, derived from pFRED143 (Ludwig, E. etal., J. Virol., 73, 8279-8289, 1999)), was cloned in frame at the 3′ end(c-terminus) of KASPP/LRRK2.

Cell Culture

HEK293 cells were cultured in DMEM supplemented with 10% FBS at 37° C.and 5% CO₂. For immuno precipitation (IP), tandem affinity purificationor cell fractionation experiments cells were transfected with Effectene®(Qiagen) and kept under full medium for additional 48 h.

Electrophoresis and Immunoblotting

For immunoblotting analyses protein samples were separated by SDS-PAGEand transferred onto Hybond-P PVDF membranes (GE Healthcare). Afterblocking non-specific binding sites with 5% dry milk in TBST (1 h, RT)(25 mM Tris pH 7.4, 150 mM NaCl, 0.1% Tween-20) membranes were incubatedovernight at 4° C. with primary antibodies in blocking buffer (mouseanti-Bip/GRP78 (BD), 1:1000; mouse anti-p50^(cdc37) (BD), 1:1000; ratanti-HA 5F10, 1.3 μg/ml; mouse anti-p97/VCP (Progen), 1:1000; rabbitanti-PMP70 (Prof. Dr. A. Völkl, University of Heidelberg, Germany),1:1000; rabbit anti-Sec61α (Acris), 1:1000; mouse anti-TOM20 (BD),1:1000; mouse anti β-tubulin (Sigma), 1:2000), washed with TBST andincubated for 1 h with horseradish peroxidase (HRP)-coupled secondaryantibodies. Membranes were washed and antibody-antigen complexes werevisualized using the ECL+chemiluminescence detection system (GEHealthcare) on Hyperfilms (GE Healthcare). For the HA epitope themonoclonal anti HA 5F10 (Roche) was used in a concentration of 1.3 μg/ml(5% dry milk). For the FLAG epitope, the HRP-coupled monoclonalanti-FLAG M2 antibody (Sigma) was used in a dilution of 1:1000 (5% drymilk) Further antibodies are used with the following dilutions: mouseanti β-Tubulin (Sigma) 1:2000; rabbit anti Sec61-α (Acris) 1:1000; mouseanti TOM20 (BD) 1:1000; mouse anti Bip/GRP78 (BD) 1:1000; mouse antip97/VCP (ProGen) 1:1000).

Cell Fractionation

Cells were harvested via trypsinisation, washed once with cold PBS,resuspended in cold homogenisation buffer (20 mM HEPES pH 7.4, 10 mMKCl, 1.5 mM MgCl₂, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 250 mM sucrose,protease inhibitor cocktail (Roche)) and homogenized. Homogenates werecentrifuged at 700×g for 10 min to pellet nuclei, debris, andnon-disrupted cells (cell pellet). The supernatant was centrifuged at10,000×g for 20 min to obtain the 10K pellet. Cytosol and 160K pelletwere prepared by ultracentrifugation of the 10K supernatant (160,000×gfor 1 h).

Carbonate Extraction

160K fractions were diluted with 100 mM (final concentration) sodiumcarbonate pH 11.5 and for 30 min on ice. The suspensions werecentrifuged for 1 h at 160,000×g at 4° C. The supernatants wererecovered and proteins precipitated with 10% trichloracetic acid.Membrane pellets and precipitated proteins were subjected to SDS-PAGEand Western blotting analyses.

Immuno Precipitation (IP)

For interaction assays FLAG-tagged KASPP/LRRK2 was lysed for 1 h inlysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% Nonidet-P40,protease inhibitors (Roche), 1 mM orthovanadate) for 1 h at 4° C. Aftersedimentation of nuclei (10 min, 10.000 g, 4° C.), the supernatant wasincubated with anti FLAG M2 agarose beads (Sigma) for 2 h at 4° C. Afterincubation, beads were washed 4× in lysis buffer and eluted with SDS-gelsample buffer.

Tandem Affinity Purification

The tandem affinity purification was done with a c-terminal tandemaffinity purification tag consisting of a tandem StrepII tag and a Flagepitope (Strep/Flag-tag). HEK293 cells transiently expressing theStrep/Flag-tagged constructs were lysed in 50 mM Tris-HCl pH 7.4, 150 mMNaCl, 0.5% Nonidet-P40, protease inhibitors and 1 mM orthovanadate for 1h at 4° C. Following sedimentation of nuclei, the cleared supernatantwas incubated for 2 h at 4° C. with streptactin superflow (IBA). Priorto washing, the lysates with suspended resin were transferred tomicrospin columns (GE Healthcare). Washing (1× with lysis buffer and 2×with TBS) was done in the microspin columns. Washing solution wasremoved from the columns by centrifugation (10 s, 2,000×g) after eachwashing step. Protein baits were eluted with desthiobiotin (2 mM inTBS). The eluates were used for LRRK2 co-precipitation experiments ofLRRK2-Strep/Flag constructs vs. LRRK2-HA.

For MS analysis, a second purification step was added. For this step,the eluates were transferred to anti-Flag M2 agarose (Sigma) andincubated for 2 h at 4° C. The beads were washed 3× with TBS inmicrospin columns. Proteins were eluted with Flag peptide (Sigma) in PBSat 200 μg/ml peptide. After purification samples were separated bySDS-PAGE and stained with colloidal coomassie according to standardprotocols prior to MS identification (Neuhoff, V. et al.,Electrophoresis, 9, 255-262, 1988).

Mass Spectrometry

The proteins were identified by MALDI-MS and MSMS on an AB3700 (AppliedBiosystems) instrument. Tryptic in gel proteolysis was done afterstandard protocols (Shevchenko, A. et al., Anal. Chem. 68, 850-858,1996). Peptides were spotted on steal targets with the dried dropletmethod using alpha-cyano-4-hydroxycinnamic acid (Sigma) as matrix(Shevchenko, A. et al., supra). Obtained MS and MS/MS spectra wereanalysed by GPS explorer software suite (Applied Biosystems).

Kinase Activity Assays (Autophosphorylation Assay)

For kinase assays (autophoshorylation assays), Strep/Flag-taggedfull-length wild-type LRRK2 or LRRK2-I2020T variant were transientlyexpressed in HEK293 cells (4x14 cm culture dishes per construct, 2×14 cmdishes for the vector control). After cell lysis and removal of thenuclei, the purification of LRRK2 variants was done byimmunoprecipitation with anti-Flag M2 agarose. The resin was washed 3×in lysis buffer. The tagged proteins were not eluted, since the kinaseassays were directly performed on the resin. Each sample was divided in4 aliquots and stored in TBS+10% glycerol at −80° C. until use.

For the kinase assay, one aliquot of each condition (wild-type LRRK2 andLRRK2-I2020T) was divided into three sub-aliquots (1/2, 1/3, 1/6). Eachsub-aliquot, as well as one aliquot of the vector control was incubatedwith 50 μM ATP, 0.3 μCi [γ-³²P] ATP in 30 μl assay buffer (25 mMTris-HCl pH 7.5, 5 mM β-glycerophosphate, 2 mM DTT, 0.1 mMorthovanadate; 10 mM MgCl₂; Cell Signaling) for 1 h at 30° C. Reactionwas stopped with Laemmli buffer. Protein samples were resolved bySDS-PAGE and transferred onto Hybond-P PVDF membranes (GE Healthcare).Imaging was done on a phosphoimager system (BioRad). Equal loading wasensured by Western blotting analyses (anti-Flag M2).

Immunofluorescence

HEK293 cells were grown on glass coverslips prior to transfection withGFP-tagged wild-type LRRK2. To avoid cell detachment, coverslips werepre-treated with poly-D-lysine (Sigma) and laminin (Sigma). 48 hpost-transfection cells were fixed for 15 min with 4% paraformaldehydeat RT. Fixed cells were permeabilised with PBS containing 0.1% Triton-X100 for 5 min, blocked with PBS containing 0.1% Tween-20 and 1% BSA andincubated 3 h at RT with primary antibodies in blocking solution [mouseanti-58K Golgi, 1:100 (Abeam); mouse anti-PDI (protein disulfideisomerase), 1:100 (Abcam); rabbit anti-PMP70 (70 kD peroxisomal membraneprotein), 1:200; mouse anti-TOM20 (translocase outer mitochondrialmembrane protein), 1:500 (BD); mouse anti-β-Tubulin, 1:500 (Sigma);mouse anti-Vimentin, 1:200 (Sigma)]. Coverslips were rinsed six timeswith PBS and labelled for 1 h with alexa 568-conjugated goat anti-mouse,goat anti-rabbit IgG (Invitrogen) or Phalloidin-TRITC (1:10,000, Sigma).For nuclear staining the solution also contained 1 μg/ml4,6-diamnodiphenyl-2-phenylindole (DAPI, Sigma). Coverslips were washedsix times with PBS, mounted with FluorSave (Calbiochem) and evaluated byfluorescence microscopy using a Zeiss Apotome equipped with Cy3, FITCand Dapi optical filter sets. The obtained images provide an axialresolution comparable to confocal microscopy (Garini, Y. et al., Curr.Opin. Biotechnol., 16, 3-12, 2005).

Results

KASPP/LRRK2 is a Membrane-Associated 280 kD Protein

For functional and biochemical studies, KASPP/LRRK2 was cloned fromhuman cDNA and generated a series of constructs for the expression ofHemagglutinin (HA), Strep/Flag and green fluorescent protein(GFP)-tagged LRRK2 fusion proteins (FIG. 12A). HEK293 cells that weretransiently transfected with c-terminal Strep/Flag-tagged wild-typehuman KASPP/LRRK2, express a ˜280 kD protein recognised by anti-Flagantibody (FIG. 12B). The observed molecular weight corresponds to thatexpected for KASPP/LRRK2. An additional weaker signal could be alsodetected in some cases at ˜180 kD that is most likely an N-terminaldegradation product of KASPP/LRRK2.

In order to determine the subcellular localisation of KASPP/LRRK2, twoapproaches were used: subcellular fractionation and fluorescencemicroscopy. For detection of the subcellular distribution of KASPP/LRRK2in vitro, transfected cells were fractionated by differentialcentrifugation. The distribution of subcellular organelles in theobtained fractions was then analysed by antibodies specific formitochondria (TOM20), cytoskeleton (β-tubulin), peroxisomes (PMP70),microsomes (BiP/GRP78, Sec61α) and soluble cytosolic proteins(p50^(cdc37)). LRRK2 was found only in membranous fractions (both 10Kand 160K pellets), i.e., fractions enriched in mitochondria (10K pellet)and microsomal membranes (160K pellet) but was absent from the cytosol(FIG. 13A).

In order to investigate whether KASPP/LRRK2 is a membrane-associated oran integral membrane protein, the 160K pellet was treated with sodiumcarbonate, pH 11.5 (Fujiki, Y. et al., J. Cell Biol., 93, 97-102, 1982).KASPP/LRRK2, together with other known membrane-associated proteins, theluminal ER marker BiP/GRP78 (78 kD glucose regulated protein) andperipheral cytosolic ER-associated marker VCP (valosin-containingprotein), was extracted from microsomal membranes, whereas the integralmembrane protein Sec61α was recovered in the membrane pellet (FIG. 13B).This provides evidence for KASPP/LRRK2 being a membrane-associatedprotein rather than integrated into membranes.

Additionally, HEK293 cells that expressed recombinantlyStrep/Flag-tagged KASPP/LRRK2 kinase-domain were subjected tosubcellular fractionation. In contrast to full-length KASPP/LRRK2, thekinase-domain construct was found in the cytosol, whereas little or nofusion-protein was detected in the particulate fractions (both, 10K and160K pellet, FIG. 13A). Thus, the kinase-domain is not implicated in theassociation of KASPP/LRRK2 to membranous structures.

LRRK2 Co-Localises with Discrete Cytoplasmic Structures

Immunofluorescence microscopy was used to determine the subcellularlocalisation of GFP-tagged KASPP/LRRK2 transiently expressed in HEK293cells. After fixation, cells were permeabilised and co-immunolabelledwith antibodies specific for distinct subcellular structures. In HEK293cells, GFP-tagged KASPP/LRRK2 demonstrated a cytoplasmic distribution(FIG. 314 column 2). Partial co-localization was observed with innercellular structures, i.e., mitochondria (TOM20), ER (PDI) and Golgi (58KGolgi). In contrast, no overlap was observed with peroxisomes (PMP70).No co-localization was found with the actin cytoskeleton(Phalloidin-Tritc) and intermediate filaments (Vimentin). However, thestrongest co-localisation was an overlap with β-tubulin, suggesting aninteraction between KASPP/LRRK2 and the microtubular cytoskeleton. Thus,KASPP/LRRK2 is a cytoplasmic protein associated with a subset of innercellular membranes, i.e., mitochondria, ER and Golgi, and with themicrotubular cytoskeleton.

Autophosphorylation Levels Between I2020T Mutant and WildtypeKASPP/LRRK2

Kinase-domain signatures can be easily detected by bioinformaticaltools. Nevertheless, it is necessary to verify the kinase activity ofKASPP/LRRK2 by biochemical assays. Furthermore, a comparison of wildtypeand mutated KASPP/LRRK2 will contribute to the understanding of themutation's nature, whether it is a gain- or loss of function mutation.

The wildtype full length protein vs. the I2020T mutant variant wastested for its ability for auto-phosphorylation. No significantdifferences in the autophosphorylation levels have been observed betweenthe I2020T variant and the wild-type (FIG. 8). This confirms that both,KASPP/LRRK2 and the disease-associated mutation I2020T in the kinasedomain of KASPP/LRRK2, possess kinase activity. Quantification ofautophosphorylation rates revealed an increase in activity of the I2020Tmutant compared to wild-type KASPP/LRRK2 of about 30-50%. This findingmay be the basis for the development of an appropriate screening assayfor modulating compounds, in particular inhibitors, of the increasedkinase activity of the I2020T mutant, as e.g. further described herein.

KASPP/LRRK2 Homodimerization

The kinase domain of LRRK2 is predicted to belong to the class ofMAPKKK. A characteristic of such kinases is the formation of dimers.Moreover, for Raf-1 and MLK-3 (mixed lineage kinase 3), one of theclosest relatives of LRRK2 in vertebrates, homo-dimerisation is requiredfor activity.

In a first approach, KASPP/LRRK2 was tested for its ability to interactwith itself by co-precipitation experiments. Therefore, tandemFlag-tagged KASPP/LRRK2 baits were co-expressed with HA-tagged fulllength KASPP/LRRK2. As shown in FIG. 9 a, the full length KASPP/LRRK2bait could pull out HA-KASPP/LRRK2 whereas a bait-protein containingonly the kinase domain showed no interaction with full lengthKASPP/LRRK2. Thus, KASPP/LRRK2 interacts with itself indicatingformation of homodimers or oligomers of higher order.

In a second approach, differently-tagged KASPP/LRRK2 proteins andco-transfected HEK293 cells were utilized with two constructs forexpression of HA and the Strep/Flag-tagged KASPP/LRRK2 fusion proteins,with the intention that a certain fraction of cells expressing twodifferent KASPP/LRRK2 fusion proteins would to address the question ofdimerisation by co-precipitation experiments. In addition to thefull-length LRRK2 protein, a Strep/Flag-tagged version of the kinasedomain only was used (FIG. 12). A comparison of purifications with allthree tags showed the best results for streptactin, which almostcompletely precipitates the tagged proteins. Therefore, streptactin wasused for precipitation of KASPP/LRRK2 fusion proteins from solubilisedcells co-expressing HA and Strep/Flag-tagged KASPP/LRRK2. As shown inFIG. 15A (lower part) by an anti-Flag antibody, both, the full-lengthand the KASPP/LRRK2 kinase domain baits were precipitated with the sameefficiency. Analysis of the precipitated proteins with the anti-HAantibody showed that only the full-length KASPP/LRRK2 bait could pullout HA-tagged KASPP/LRRK2, whereas the kinase domain did not display anyinteraction with full-length KASPP/LRRK2 (FIG. 15A, upper left panel).Thus, only full-length KASPP/LRRK2 interacts with itself forminghomodimers or oligomers of higher order.

KASPP/LRRK2 Interaction with HSP90 and its Co-chaperone p50^(cdc37)

To identify proteins which interact with the KASPP/LRRK2 kinase domaintandem affinity purification experiments were performed with a tagsystem. The purified protein complexes were subjected to SDS page (FIG.9 b). The interacting proteins were identified using mass spectrometry.As shown in FIG. 10 b the isolated kinase domain of KASPP/LRRK2 isassociated with HSP90 and its co-chaperone p50^(cdc37). The full-lengthKASPP/LRRK2, however, binds to HSP90 and p50^(cdc37) to a very lowextend. The interaction with the HSP90/p50^(cdc37) chaperone-system isshown for several kinases, including the MAPKKK Raf-1 and MLK-3. In bothinstances, they do not serve as substrates but associate as chaperonesparticipating in maintenance of proper folding of the kinase. Thisexperiment is a further evidence that KASPP/LRRK2 possesses kinaseactivity and is active in transfected cells.

KASPP/LRRK2 Association with Microsomal Membranes

Information of the localization of KASPP/LRRK2 will help to understandits in vivo function. Using fluorescence microscopy experiments with ac-terminal GFP tagged construct it was shown that KASPP/LRRK2 iscytoplasmic distributed in HEK293 and COST cells (FIG. 10). By immunoco-staining there was no clear co localisation observed with anycellular structure like cytoskeleton or organelles. However, byco-staining with TOM20 and TIM23 partial overlap with mitochondria wasobtained.

To further analyze the subcellular localization of this protein, a cellfractionation was performed (FIG. 11 a). Surprisingly, no KASPP/LRRK2was found in the cytosol. However, high amounts of KASPP/LRRK2 werefound in the analyzed membranous fractions (both 10K and 160K pellets),i.e. fractions enriched with mitochondria (10K-pellet) and microsomalmembranes (160 k pellet).

In order to test if KASPP/LRRK2 is an integral membrane or amembrane-associated protein, carbonate extraction of the microsomalmembrane fraction (160K pellet) was applied. Since KASPP/LRRK2 could beextracted with carbonate (FIG. 11 b) it is a membrane-associated proteinrather than being integrated into the membrane. Thus, KASPP/LRRK2 is aprotein with cytoplasmic but not cytosolic distribution and demonstratesstrong association to membranes.

GENERATION OF MONOCLONAL ANTIBODIES AGAINST KASPP/LRRK2

General

The immunization, generation of hybridoma clones and ELISA for positiveclones against peptide #2025 used for the immunization were carried outaccording to standard protocols. The antibody producing clones weretested for sensitivity and specificity against KASPP/LRRK2. Peptide#2025 with the amino acid sequence “CRMGIKTSEG TPGFRAPEVA RGNVIYNQQA D”(SEQ ID NO:3) represents the kinase domain of KASPP/LRRK2 (amino acidsNos. 2025-2055). This particular peptide was chosen because the homologyof the sequences between mouse and human is 100%.

Test Conditions for Sensitivity and Specificity of the GeneratedAntibodies

A lysate of HEK293 cells overexpressing recombinant KASPP/LRRK2 and acontrol lysate of HEK 293 cells transfected with an empty vector wereseparated in a PAGE gels (8%). The probe was applied in a broad slotover the whole gel. After electrophoretic separation the separatedlysates were transferred on PVDF membranes (western blot procedure).After the transfer the membranes were first blocked with blocking buffer(5% low-fat milk powder, BioRad, in TBS-Tween 20) for 1 h with theeffect that unspecific adsorption of the antibodies to the membrane wasavoided. Thereafter the blots were incubated with the positively testedhybridoma supernatants for 3 h (ELISA for testing the affinity to thepeptide). The incubation was carried out in a multiscreen chamber(BioRad). The chamber allows the incubation of a blot with differentprimary antibodies. The membranes were taken form the chambers forwashing (4×5 min in TBST buffer). Then. the incubation was carried outwith a HRP (horse reddish peroxidase) coupled secondary antibody (antirat IgG) for 1 h. After the incubation the blots were washed with TBST(4 ×10 min). The detection of the antibody reaction was done with thehelp of chemolumineszenz (ECL+, GE Healthcare) and exposition of a film(hyperfilm, GE Healthcare).

Result

The results of the above described Western blots are shown in FIG. 16.Clone 3G6 (No. 10) and 4B7 (No. 15) (peptide #2025) produced a specificsignal. A signal was specific if (a) it appeared at the position of thecorrect molecular weight (280 kD) and (b) it appeared stronger or onlyfor the lysate of the KASSP/LRRK2 overexpressing cells.

TABLE 1 Gene Symbol Accession Nr. PKP2 NM_001005242 ALG10 NM_032834CPNE8 NM_153634 KIF21A NM_017641 ABCD2 NM_005164 FLJ40126 NM_173599SLC2A13 NM_052885 KASPP/LRRK2 MUC19 AY236870 CNTN1 NM_001843 PDZRN4NM_013377 LOC283464 BC039145 YAF2 NM_005748 MADP-1 NM_033114 PPHLN1NM_201438 PRICKLE1 NM_153026 ADAMTS20 NM_025003 DKFZp434G1415 NM_031292IRAK4 NM _016123 PTK9 NM_002822 DKFZp434K2435 NM_032256 NELL2 NM_006159PLEKHA9 NM_015899 DKFZp451M105 AL832340 FLJ14711 AK027617 FLJ22820AK026473 SLC38A1 NM_030674 SLC38A2 NM_018976 SLC38A4 NM_018018

TABLE 2 Location Forward Reverse D12s2194 F_GAGGACTATGATTGCCATGGR_AGGGCATACAAAATGTCCCT D12s1048 F_GGTCTGCTTAGGTCCCTTTTR_AAGGAACCAAGGAGTGGAAG Intragenic_1 F_TTCAGATGTTTGGGGCAAGTR_CATGAAGACTGTGAATGGTTTG Intragenic_2 F_CCAGACAGAAGTCTGAAGGACAR_TCCAAAACAGACAAGAGGTTGA Intragenic_3 F_ATGAAGCCTTGGCTCTTCAAR_TCCCAATTCAAAATTTTAGTGC

TABLE 3 PD Families Idiopathic Controls Variant Exon (n = 55) PD (n =337) (n = 1200) Family R793M; 19 2 1 1 DE041 2378G>T T11239 Q930R; 21 10 0 DE022 2789A>G S1096C; 24 1 0 0 famE 3287C>G L1114L; 24 1 0 0 DE0383342A>G T11288 S1228T; 27 1 0 0 DE031 3683G>C G2019S; 41 0 1 0 HernandezDG 6055G>A et al. (2005) I2020T; 41 1 0 0 DE032 6059T>C T10738

TABLE 4 Family/Patient DE022/ DE041/ III-5// T11239 II-1//II-2III-6//III-7 Fam. E T11288/II-5 DE031/III-1//III-2 T10738/II-2 MutationR793M R793M Q930R S1096C 3342A > G S1228T 12020T Age at onset (y) 4255//70 68//58//47 77 49//49 57 uncle: 79 father: 62 father: 59 granny:68 Disease duration 25~ 14~//10~ 8~//19//30 4~ 8~//12~ 3~ Initial symtomB/RT PT//RT B, RT//B// B RT//B, RT B, RT B, RT Response to L- + +//++//+//+ + + +//+ + dopa Bradykinesia + +//+ +//+//+ + +//+ + Rigidity ++//+ +//+//+ + +//+ + Resting Tremor + −//+ +//+//+ − +//+ + Postural ++//+ −//+//+ + −//− − instability Sleeping + +//− +//+//+ + −//+ +disturbances Long-term + +//+ +//+//+ − +//+ − complicationsHallucinations + −//− −//−//+ + −//− − Additional Tongue − Dementiafindings dystonia L-dopa hypersensitivity Sniffing test 2/8 nd nd nd 7/85/8//5/8 7/8 Electro- na nd nd nd na na//na Na neurography Electro- nand nd nd na na//na Na myography Magnet evoked na nd nd nd na na//na Napotentials TCS (r; l) 0.21; 0.24 nd nd nd 0.24; 0.19 0.23; 0.24// 0.16;0.17 0.22; 0.24 MRI nd, nd nd nd global atrophy, slightly increasedatrophy in Slight because of microangiopathy both, slightmicroangiopathie frontotemporally electrodes in III-2 enhanced atrophy

TABLE 5 Family/Patient T11239 T11288/II-5 DE031/III-1// DE031/III-2T10738/II-2 Mutation R793M 3342A > G S1228T 12020T LPS-K/SPM (IQ) /90↓75↓↓/ 111↑/ 117↑/ 120↑/ Tower of London (PR) xx — 6↓↓ 27↓ xx CWIT(T-Value INT) — (63) 37 41 41 CERAD 1 (Verbal Fluency) —  6 20~ 31↑ 36↑CERAD 2 (Boston Naming Test) — 12 14~ 15~ 14- CERAD 3 (MMSE) 22 24 30~30~ 29~ CERAD 4 (Word List Memory) — 10 19~ 22~ 29↑ CERAD 5(Constructional Praxis) —  7 10~ 10~ 11~ CERAD 6.1 (Word List Recall) — 1  7~  7~ 10↑ CERAD 7.1 (Word List Recognition) — 10  9 10 10 CERAD 8(Recall of Constructional Praxis) —  2 10~ 13↑ 12↑ D2-Test(Concentration) — — 38 46 46 BDI 23↑ 11  3  9  7.5 PDQ-39 (PDSI) 40.425.6  8.8 18.6 23.6

The invention claimed is:
 1. A method of detecting a mutation atposition 4321 in the nucleic acid molecule of SEQ ID NO: 1 or 2 in asample, the method comprising: (a) contacting a sample with a probeconsisting of 10 to 50 nucleotides for the detection of said mutation,wherein said probe hybridizes under high stringency conditions to any ofthe polynucleotide sequences (i), (ii), (iii), (iv), or (v): (i) apolynucleotide sequence selected from nucleotides 1 to 9104 of SEQ IDNO: 1 or 2; (ii) a polynucleotide sequence selected from nucleotides 1to 7584 of SEQ ID NO: 1 or 2; (iii) a polynucleotide sequence selectedfrom nucleotides 1 to 7581 of SEQ ID NO: 1 or 2; (iv) a polynucleotidesequence selected from a nucleotide sequence coding for the proteinsequence of SEQ ID NO:8 or 9 or for the protein sequence of SEQ ID NO:8or 9 containing at least one of the mutations depicted in SEQ ID NO: 1or 2; or (v) a polynucleotide sequence selected from a nucleotidesequence complementary to any of the nucleotide sequences of (i), (ii),(iii), or (iv): wherein the polynucleotide sequence codes for theprotein sequence of SEQ ID NO. 8 or 9 containing a mutation at position1441, and wherein said high stringency conditions comprise hybridizationat 68° C. in a solution comprising 50% formamide, 5×SSC (Sodium andsodium Citrate buffer) or 5× SSPE (Sodium, Sodium Phosphate, and EDTAbuffer at pH 7.7), 5× Denhardt's solution, 1% Sodium Dodecyl Sulfate(SDS), and 100 μg/ml denatured salmon sperm DNA, followed by washing at68° C. in a buffer comprising 0.2 SSC and 0.1% SDS, and (b) detectingthe presence of the mutation in the nucleic acid of the sample.
 2. Themethod of claim 1, wherein the sample is selected from (a) a biopsy fromhuman tissue or cells; or (b) RNA or DNA from a biopsy from human tissueor cells.
 3. The method of claim 1, wherein the detecting of themutation comprises Southern blot hybridization, Northern blothybridization, PCR, RT-PCR, real-time RT-PCR or automated sequencing. 4.The method of claim 1, wherein the detecting of the mutation comprisesradiography, fluorescence, chemiluminescence, or any combinationthereof.
 5. The method of claim 1, wherein the method is carried out onan array.
 6. The method of claim 1, wherein the method is carried out ina robotics system.
 7. The method of claim 1, wherein the method iscarried out using microfluidics.
 8. The method of claim 1, wherein saidprobe consists of 10 to 35 nucleotides.
 9. The method of claim 1,wherein said probe consists of 20 to 35 nucleotides.
 10. The method ofclaim 2, wherein said sample is from the brain.
 11. The method of claim10, wherein said sample is from putamen or substantia nigra.
 12. Themethod of claim 2, wherein said sample is from heart, lung, or bloodlymphocytes.
 13. The method of claim 2, wherein said RNA or DNA is fromthe brain.
 14. The method of claim 13, wherein said RNA or DNA is fromputamen or substantia nigra.
 15. The method of claim 2, wherein said RNAor DNA is from heart, lung, or blood lymphocytes.
 16. The method ofclaim 1, wherein said method is diagnostic of a neurodegenerativedisorder selected from the group consistent of Parkinson disease (PD),sporadic PD, Alzheimer disease (AD), amyotrophic lateral sclerosis(ALS), synucleinopathy, and tauopathy.